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Abstract 
Incorporating proteins with nanomaterials is an effective way to enhance the stability and 
function of proteins. The protein-nanomaterials hybrid systems have been extensively 
applied in drug delivery and biocatalysis. This thesis focuses on the different interactions 
between proteins and nanomaterials. Three sub-projects have been studied as follows; 
1) Chemical interaction: Gold nanoparticles with a particle size of 15nm were applied to 
label bovine serum albumin (BSA), a globular protein, for realizing a colorimetric protein 
assay. The results of FTIR and Raman spectra indicate that gold nanoparticles bond to BSA 
via the amine bonds. The surface plasma resonance (SPR) of gold nanoparticle labelled BSA 
shows a linear relationship with the concentration of BSA. 
2) Electrostatic interaction: To make enzyme stable and recyclable in biocatalysis, the 
enzyme, carbonic anhydrase (CA), was immobilized on zinc oxide (ZnO) nanorods via 
electrostatic interaction. The highest immobilization ratio (60%) is achieved at pH 8.0. The 
CO2 capturing by the immobilized CA has been investigated. It is found that a 2.2×2.2cm 
ZnO nanorod chip with 0.75mg immobilized CA could capture up to 6mmol CO2 in 100mL 
water. 
3)  Multiple interactions: Via hydrogen bond and electrostatic interaction, basic fibroblast 
growth factor (bFGF) was incorporated within chitosan and silica nanoparticles, respectively. 
In vitro release tests indicate that chitosan and silica nanoparticles could achieve a sustained 
bFGF release up to 230 and 180 hours, respectively. The bFGF-loaded nanoparticles were 
afterwards immobilized within HEMA hydrogel. The nanoparticle-HEMA nanocomposites 
can provide a localized sustained protein release without systematic absorption. 
The incorporation of proteins with nanomaterials can enhance the stability and activity of 
proteins which are otherwise prone to denaturation.  
Keywords 
Nanoparticle, Gold, Protein Assay, Zinc Oxide, Carbonic Anhydrase, Hydrogel, Chitosan, 
Silica 
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Chapter 1  
Introduction, Motivation and Objective 
1.1 Introduction 
The improvement of modern biotechnologies leads to a significant increase in the 
application of proteins in bio-medicine and in bio-catalysis. For example, the genetic 
recombination technology has brought a remarkable expansion in the application of 
proteins in the treatment of a myriad of disease 
[1]
.  In addition, the progress in directed 
evolution 
[2]
 and high-throughput screening 
[3] 
techniques has enabled the broad 
application of enzyme catalysts in the chemical industry to manufacture products ranging 
from simple commodity chemicals to pricy drug substances 
[4]
.  It is noted that protein 
activities are highly dependent on its flexible and sensitive conformational structures. 
External factors such as pH, temperature, surface interaction, as well as contaminants, 
may compromise the conformational and even the chemical structure of proteins 
[5]
. 
The flexible and instable structure of proteins usually hinders their applications: 1) 
Industrial applications of enzymes for bio-catalysis are usually at high temperature, high 
salt concentrations, as well as in the presence of surfactants 
[6]
. Only few enzyme 
catalysts are able to withstand such extreme conditions. 2)  In many instances, the high 
solubility of some protein enzymes in reaction media may prevent them from being 
recycled and reused with current standard reactors in an economically feasible way. 3) 
Human body fluids contain a myriad of enzymes, hormones, cells and metabolites. 
Protein may be absorbed to or be cleft by those components and lose activities rapidly 
after being administered 
[7]
.   
Incorporating protein within nanomaterials provides a promising solution to overcome 
those barriers met by bio-medical and bio-catalytic application of proteins. Nanomaterials 
are materials with at least one of their dimention in the range of 1-100 nm. The large 
surface area-to-volume ratios of nanomaterials, such as nanoparticles and nanorods, make 
them potentially highly efficient protein carriers 
[8,9]
.  
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Among nanomaterials, nanoparticles are usually used as drug delivery systems and 
enzyme immobilization supporters. These nanoparticle-based systems are stable, non-
toxic, non-immunogenic, and biocompatible 
[10, 11]
.  Incorporating proteins into those 
nanoparticles can improve their stability 
[12, 13]
, retend their release rate 
[13]
 and direct 
them to certain organs and tissues 
[14]
. Nanorods are often utilized as enzyme 
immobilization supporters for bio-catalysis. Attachment of soluble enzyme to insoluble 
nanorods substrate improves enzyme stability and activity 
[15, 16]
, and makes the efficient 
enzyme reuse economically feasible. The immobilized enzymes are usually used as 
biosensor for the detection of various small molecules such as glucose 
[17]
 and phenol 
[18]
. 
Proteins are incorporated to nanomaterials in three different ways: being attached to 
surface, embedded into the porous scaffold, or encapsulated inside the materials. Various 
protein-nanomaterials interations participate in the incorporation process. The most 
common ones are chemical interaction, hydrogen bond and electrostatic interaction 
[19]
.  
Many ligands in proteins molecules, such as thiols, disulfides, phosphines, amines, and 
carboxylates, are able to interact with gold nanoparticles and form chemical bonds with 
similar strength to covalent bonds 
[20]
.  Additionally, the surface plasmon resonance 
indigenous to gold nanoparticles makes them show a strong and stable red color after 
protein binding
 [21]
.  This easily detectable color and tight protein binding allow gold 
nanoparticles to be a potential protein label for quantitative protein assay. 
Electrostatic interaction is the most common protein-nanoparticle interaction 
[19]
.  Some 
proteins are amphiprotic molecules, while the surfaces of nanoparticles can be modified 
with positively or negatively charged function groups. By adjusting the environmental pH 
value, proteins and nanomaterials could be oppositely charged. The resultant static 
electriciry force makes proteins tightly bind to nanomaterials.  
Hydrogen bonding is the electromagnetic attractive interaction of a hydrogen atom and an 
electronegative atom, such as nitrogen or oxygen that comes from another chemical 
group. Hydrogen bonds provide most of the directional interactions that underpin protein 
folding, protein structure and molecular recognition 
[22]
. In contacting with nanomaterials 
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rich in functional groups, proteins could easily be incorporated into the nanomaterials via 
hydrogen bond.  
1.2 Motivation  
1.2.1 Protein-nanoparticle binding via chemical interaction 
The nature of the chemical interaction between proteins and gold nanoparticles makes 
incorporated proteins unlikely to be detached from their carriers. Other than the more 
popular application as a protein delivery system, the gold nanoparticle could be utilized 
as a protein label for colorimetric protein assay. 
The accuracy of current standard colorimetric protein assay methods is usually interfered 
by factors such as protein structre, purity and the existence of other molecular 
[23]
. 
Because of their strong surface plasma resonance, gold nanoparticles are readily 
detectable by spectrometers. The multiple high-strength bonds of protein to gold 
nanoparticles may make the resultant protein-gold nanoparticle complex independent of 
the interferencing factors that compromise the accuracy of other standard colorimetric 
protein assay methods.   
The concentration of gold nanoparticles could be easily quantified by measuring the 
intensity of their surface plasma resonances. By fixing the ratio of protein to gold 
nanopartilcles, the concentration of loaded protein could be easily calculated by 
multiplying the protein to gold nanopartilcle ratio with gold nanopartilcle concentration 
1.2.2 Protein-nanomaterial binding through electrostatic interaction 
The electrostatic interaction between oppositly charged protein and nanomaterial is 
usually strong and stable. Such tight and stable protein-nanomaterial binding could be 
applied to get an enzyme-nanomaterial complex that is resistant to the environmental 
turbulence present in reactors.  
The biosafety and biocompatibility of zinc oxide (ZnO) make ZnO nanorod a superb 
material for enzyme immobilization 
[24]
.  The isoelectric points (pI) of the model enzyme, 
carbonic anhydrase (CA), and ZnO are 6.7-7.9 
[25]
 and 9.5, respectively. Incubating CA in 
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the presence of ZnO nanorods in a medium which could make them oppositely charged 
could incorporate CA onto ZnO nanorods via electrostatic interaction. Such immobilized 
enzymes are more stable and easier to be reused than free enzymes.  
1.2.3 Protein-nanomaterial binding via multiple interactions 
Due to their complex nature, proteins are usually incorporated with nanomaterials 
through multiple interactions, especially electrostatic forces and hydrogen binding.   
Chitosan is a polymer with both positively charged side chains and rich amino and 
hydroxyl groups. Protein could be incorporated into chitosan nanoparticles via 
electrostatic forces and hydrogen bonding 
[26, 27]
. Silica nanoparticles are characterized by 
their honeycomb-like porous structure with hundreds of empty channels. It is reported 
that proteins are absorbed onto silica through multiple binding: 1) Protein’s carbonyl 
groups interact with silica’s vicinal hydroxyl groups via electrostatic interaction. 2) Imido 
groups in proteins form hydrogen bonds with individual hydroxyl groups on silica surface 
[28]
. The obtained protein-nanomaterial complexs are usually used as protein delivery 
systems.  
1.3 Objectives 
The objective of this research is aimed at investigating the protein-nanomaterial 
interactions via protein-nanomaterial complexes. Based on specific protein-nanomaterial 
interations, corresponding protein carriers are developed and their characteristics, 
activities and possible applications are investigated.  It can be divided into three 
individual parts: 
1) To investigate the interaction between protein and gold nanoparticles. To utilize gold 
nanoparticle as a protein label to develop a cholorometric protein assay method. 
2) To find the proper condition to immobilize protein onto nanorods through electrostatic 
interaction. To utilize the immobilized protein for CO2 capture. 
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3) To load protein into chitosan and silica nanoparticle via multiple protein-nanoparticle 
interaction. Additionally, apply the protein-loaded nanoparticles to achieve a sustained 
topical protein release. 
1.4 Outline of thesis 
Chapter 1: This chapter introduces the problems to be addressed and the techniques that 
would be used in the thesis, the motivation behind the selection of the techniques and the 
research objectives. 
Chapter 2: The literature review summarizes current application of nanoparticles as a 
protein carrier and the utilization of nanoparticles and nanorods as substrates for enzyme 
immobilization. 
Chapter 3:  This chapter introduces the experimental materials and methods. 
Chapter 4: In this chapter, the interaction of gold nanoparticles with protein is 
investigated and the gold nanoparticle is exploited as a protein label.  Bovine serum 
albumin is used as model protein. Release pattern of gold nanoparticle labeled BSA from 
gelatin microspheres is studied.  
Chapter 5: This chapter looks into the protein immobilization onto ZnO nanorods. 
Electrostatic force is utilized to immobilize carnonic anhydrase, the model protein onto 
ZnO nanorods. CO2 capturing ability of the obtained system is studied.   
Chapter 6: In this chapter, model protein bFGF is incorporated into chitosan and silica 
nanoparticles via multiple protein-nanomaterial interaction. The bFGF loaded 
nanoparticles are applied in combination of hydrogel to achieve a sustained topical bFGF 
delivery. 
Chapter 7: This chapter summarizes the research and puts forward the future work. 
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Chapter 2  
Literature  Reviews 
Nanomaterials are materials with at least one of their dimention in the range of 1-100 nm 
[1]
. Being complex mixtures, they may absorb light like a dye and appear to dissolve like 
any other small molecules. Their actual behaviours are often different and are usually the 
result of the different components of the material 
[2]
. Nanomaterials have an exceptionally 
high surface area to volume ratio; this is one of the reasons for some of their unusual 
properties 
[3]
. In many cases the exact composition of the surface of the nanomaterials 
dictates their final applications 
[4,5]
. For example, a nanoparticle designed to interact with 
biological systems will have suitable functional groups attached to its surface 
[6]
. 
Nanomaterials are used for various fields such as fiber and textiles 
[7]
, agriculture 
[8-10]
, 
energy 
[11,12]
, and biomedical sciences 
[13-15]
.  In biomedical applications, nanomaterials 
are usually used as protein carriers. Such carriers are superior to other more traditional 
ones in many aspects: They can insulate proteins from interaction with the environment, 
protect proteins from premature degradation, enhance proteins’ absorption and 
bioavailability, and improve proteins’ intracellular penetration [16]. As for the bio-
catalysis, nanomaterials are usually applied to immobilize enzyme catalysts. In this 
chapter, we will introduce the application of nanomaterials as protein carriers and 
supporters to immobilize enzymes. 
2.1 Nanomaterials as protein carriers 
Nanoparticles are the most investigated nanomaterial for protein delivery. Biological 
agents, such as peptides, enzyme and siRNA, face a major barrier in pharmaceutical 
application: being easily degraded, they usually have very short half lives 
[17]
.  
Nanoparticle protein carriers provide unparallel freedom to modify fundamental 
properties of those biological agents such as stability, half-life, release pattern, solubility, 
and immunogenicity. The nanoparticle based delivery of biological agents has improved 
over the years and many of them, such as liposomal verteporfin developed by Novartis, 
have made their ways into the clinic trial and commercialization 
[18]
.  A myriad of 
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materials are exist to be used as nanoparticle matrix, they can be roughly divided into two 
categories: biodegradable polymers and inorganic materials. Selection of nanoparticle 
matrix depends on the encapsulation efficiency, improvement of bioavailability and 
retention time of the final product. The desired materials are generally achieved by hit 
and trial method 
[19]
. 
2.1.1 Biodegradable polymeric nanoparticle 
Biodegradable polymeric nanoparticles are the most studied protein nano-carriers and 
many of them have been put in clinical trial or commercialized 
[18,20]
. Proteins are either 
bound to surface or encapsulated inside the nanoparticles. These nano-medicines are 
stable in blood, non-toxic, non-immunogenic, non-inflammatory, do not activate 
neutrophils, biodegradable, and applicable to various molecules such as small molecules, 
proteins/ peptides, and nucleic acids 
[21-23]
.  Countless work has been conducted to 
develop effective biocompatible and biodegradable polymers for nanoparticles. Despite 
of the large amount of developed polymers, only a very small proportion of them have 
been approved by FDA for human use. Gelatin and chitosan are two of the FDA 
approved, low cost, and safe biodegradable polymers for nanoparticles. 
2.1.1.1 Gelatin nanoparticles 
Gelatin is a biodegradable, non-toxic polymer with extensive applicationd in food and 
medical products 
[24]
.  It is obtained by controlled hydrolysis of the collagen, a major 
component of skin, bones and connective tissue 
[25]
. Both acid and alkali can be used as to 
extract gelatin. The acid-extracted gelatin is designated Type A, whereas the product of 
the alkaline extraction is referred to as Type B 
[24]
. The isoionic point for type A and B 
gelatin are 7-9 and 4-5, respectively 
[26]
. Type A gelatin has a greater intrinsic viscosity 
than that of type B. Three groups of amino acids are predominant in the gelatin molecule. 
Glycine and alanine account for about one-third to half of the total amino acid residues in 
type B and type A gelatin respectively. Meanwhile, approximately one-fourth of the 
amino acid residues in both type of gelatins are proline 
[24]
. Such structure offers many 
possibilities for chemical modification and covalent drug attachment. Both type of 
gelatine can be used as nanoparticle matrix. Gelatin nanoparticles can be prepared by 
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various techniques such as coacervation 
[27]
, desolvation/ nanoprecipitation 
[28, 29]
, and 
emulsion 
[30]
.  
Coacervation is a process during which a homogeneous solution of charged 
macromolecules undergoes liquid-liquid phase separation, giving rise to a polymer-rich 
dense phase at the bottom and a transparent solution above. Salt or alcohol is normally 
added to the solution to promote coacervation and control the degree of crosslinking that 
resulted in desired nanoparticles 
[27]
.  
Briefly, desolvation / nanoprecipitation require two solvents that are miscible. In 
desolvation process, the nonsolvent phase is added slowly to the solvent phase that 
containing polymer 
[28]
. As for the nanoprecipitation process, the solvent phase that 
containing polymer is added to the non-solvent phase 
[29]
. 
 
The interfacial turbulence 
generated during solvent displacement is the force to form nanoparticles. Subsequently a 
violent spreading is observed because of mutual miscibility between the solvents. The 
nano-sized droplets formed in the process are rapidly stabilized by the stabilizing agent, 
until diffusion of the solvent is complete and polymer solidification has occurred. For 
gelatin, the desolvation process is usually a two steps process, gelatin is first dissolved to 
make a homogeneous aquesous solution, desolvation reagent is added to the solution to 
get high molecular gelatin. The low molecular gelatin fractions present in the supernatant 
were discarded. The high molecular fractions present in the sediment were re-dissolved in 
acidic water and then desolvated to form nanoparticles 
[28]
. Crosslinkers are usually added 
at the second desolvation step to stabilize the nanoparticles. 
Emulsion method is a simple solvent evaporation technique based on a single water-in-oil 
emulsion and stabilized by the use of cross-linking agent 
[30]
. The encapsulating polymer 
is dissolved in a partially water soluble solvent which is saturated with water to ensure 
the initial thermodynamic equilibrium of both liquids. Subsequently, the polymer-water 
saturated solvent phase is emulsified in an aqueous solution containing stabilizer, leading 
to solvent diffusion to the external phase and the formation of nanoparticles. Finally, the 
solvent is eliminated by evaporation or filtration, according to its boiling point 
[31]
.  In 
fact, to produce the precipitation of the polymer and the consequent formation of 
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nanoparticles, it is necessary to promote the diffusion of the solvent of the dispersed 
phase by dilution with an excess of water when the organic solvent is partly miscible with 
water or with another organic solvent in the opposite case. 
2.1.1.2 Chitosan nanoparticles 
Chitosan is a modified natural polymer prepared by the partial deacetylation of 
crustacean derived natural biopolymer chitin 
[32]
, it is found in a variety of forms differing 
in molecular weight and degree of deacetylation. According to Kean’s reviews, no toxic 
effect was noted after chitosan is injected, subcutaneous implanted, oral administered and 
mucosa applied 
[33,34]
.  The rate and extent of chitosan biodegradation in living organisms 
are dependent on the degree of deacetylation 
[35,36]
. Increasing degree of deacetylation 
decreases the decomposition rate. It is likely that, given adequate time and appropriate 
conditions, the chitosans would degrade sufficiently for consequent excretion. Given its 
superb non-toxicity, biologically compatibility, chitosan is approved for dietary 
applications in Japan, Italy and Finland 
[37]
 and it has been approved by the FDA for use 
in wound dressings 
[38]
. Chitosan nanoparticles can be prepared by four methods: ionic 
gelation, microemulsion, precipitation and reverse micellar method 
[39]
. 
Ionic gelation is based on electrostatic interaction between amine group of chitosan and 
negatively charge groups of polyanion such as tripolyphosphate 
[40,41]
. Comparing to 
chemical cross-linking, such reversible physical cross-linking avoids the possible toxicity 
of crosslinking reagents. In the ionic gelation method, chitosan is dissolved in aqueous 
acidic solution to obtain the cation of chitosan. This solution is then added dropwise 
under constant stirring to polyanionic tripolyphosphate solution. Due to the complexation 
between oppositely charged species, chitosan undergoes ionic gelation and precipitates to 
form spherical particles. Although this method is simple, environmental friendly and easy 
for mass production, nanoparticles formed by this technique have poor mechanical 
strength. 
The microemulsion method cross-links the amine groups of chitosan with aldehydes. In 
this method, a water-in-oil emulsion is prepared by dispersing chitosan aqueous solution 
in the oil phase. Aqueous droplets are stabilized by adding surfactant. The chitosan in the 
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stable emulsion is cross-linked by cross-linking agent such as glutaraldehyde. Cross-
linked nanoparticle are filtered and washed with n-hexan 
[42,43]
.  Particle size of the 
nanoparticles is controlled by the size of aqueous droplets, the amount of cross-linking 
agent and the speed of stirring during the formation of emulsion 
[43]
. The microemulsion 
method involves long processing time as well as use of harsh cross-linking agents.  One 
hundred percent removal of the un-reacted crosslinking agent is difficult. 
The precipitation technique utilizes the physicochemical property of chitosan. Chitosan is 
soluble in acidic medium. Chitosan polymer in the acidic medium will precipitate when it 
comes in contact with alkaline medium. Nanoparticles are produced by blowing chitosan 
solution into an alkaline medium using a compressed air nozzle to form chitosan droplets 
[44]
. Separation and purification of nanoparticles was done by centrifugation followed by 
successive washing. The size of obtained nanoparticles is controlled by the compressed 
air pressure and spray-nozzle diameter. The speed of drug release is determined by cross-
linking agents. 
Reverse micellar technique can produce ultrafine polymeric nanoparticles with narrow 
size distribution 
[45,46]
. Reverse micelles are thermodynamically stable liquid mixtures of 
water, oil and surfactant. Because the size of the reverse micellar droplets is usually ultra 
fine and highly mono-dispersed, nanoparticles prepared by this method always possess a 
narrow size distribution. In reverse micellar method, the surfactant is first dissolved in an 
organic solvent, aqueous drug containing chitosan solution is added with constant 
vortexing to avoid any turbidity. To this clear solution, a cross-linking agent is added 
with constant stirring. The organic solvent is then evaporated to obtain the dry mass. The 
material is dispersed in water and the surfactant is precipitated by adding suitable salt to 
the aqueous solution. The precipitated surfactant is separated by centrifugation, and 
nanoparticles remains in supernatant solution. Nanoparticles can be separated from the 
supernatant by dialysis and lyophilization. 
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2.1.1.3 Other polymeric nanoparticles 
Besides natural biodegradable polymers such as gelatine and chitosan, some synthetic 
polymers such as PLGA and PLA also show superb safety and biocompatibility. Those 
polymers are also suitable to be made into nanoparticles.     
PLGA (poly-D,L-lactide-co-glycolide) is a FDA approved polymer for therapeutic use in 
humans. It undergoes hydrolysis in the body to produce lactic acid and glycolic acid. 
Since the two monomers are effectively metabolized by human body, there is very 
minimal systemic toxicity associated with PLGA and its metabolites 
[47]
. A variety of 
techniques can be applied to produce PLGA nanoparticles, such as emulsification 
[48]
, 
interfacial deposition 
[49]
 and nanoprecipitation method 
[50]
. As for the emulsification 
method, PLGA polymers are dissolved in organic solvent, poured and separated in 
aqueous phase having stabilizer and subsequently emulsified by homogenizer. The 
interfacial deposition is based on spontaneous emulsification of the organic internal phase 
containing the dissolved polymer into the aqueous external phase. PLGA is dissolved in a 
water-miscible solvent first. This phase is then injected into a stirred aqueous solution 
containing a stabilizer as a surfactant. The fast diffusion of the solvent causes polymer 
deposition on the interface and formation of a colloidal suspension. In nanoprecipitation 
method, organic solvent dissolved PLGA is added dropwise into continuously stirring 
aqueous phase to form a micelle, organic phase is consequently removed under reduced 
pressure.  
Polylactic acid (PLA) is a biocompatible, biodegradable substance that is synthetically 
derived from natural components. It has been used in surgical products such as 
dissolvable stitches, bone screws and cosmetic treatment of scars and wrinkles. PLA is 
degraded in the body to monomeric units of lactic acid, which is a natural intermediate in 
carbohydrate metabolism. Similar to PLGA, PLA nanoparticles can be prepared by 
emulsification 
[51,52]
, interfacial deposition 
[53]
 and nanoprecipitation method
[54]
 .  
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2.1.1.4 Application of polymeric nanoparticles 
Due to the advantages of polymeric nanoparticles such as stability, non-toxicity, and 
biodegradability, they are widely studied as a protein / plasmid carrier and applied in the 
field of non-viral gene delivery, controlled release and targeted delivery of proteins. 
Polymeric nanoparticles can sometime supersede the long used viral vectors as a gene 
delivery system. Compared to viral vectors, polymeric nanoparticles are relatively easy to 
prepare, less immunogenic, and have no potential of virus recombination. In addition, 
structurally modifying polymeric nanoparticles can adjust their delivery efficiencies. 
Gelatin nanoparticle is an effective vector to achieve gene delivery 
[55]
. Through surface 
modification, some specific characteristics can be imparted to gelatine nanoparticles such 
as prolonged in vivo circulation 
[56]
 and tumour targeting 
[57]
. Nanoparticles made from 
chitosan or chitosan derivatives also show efficient gene transfection 
[55, 58]
. 
Targeted drug delivery can achieve a high therapeutic efficiency with minimum side 
effects. By controlling the particle size or modifying particle surface properties, 
polymeric nanoparticles can be made into targeted drug delivery systems. The surface 
modicication could be accomplished through adjusting nanoparticles’ surface 
physiochemical characteristics or grafting nanoparticles’ surface with ligands that can 
bind specifically to target cells or tissues. For example, nanoparticles with hydrophilic 
surface show prolonged residing time in circulation system 
[57]
; antibody grafted 
nanoparticles accumulate specifically to the cells where matching antigens are expressed 
[59, 60]
.  
Biodegradable polymers are also broadly investigated as controlled drug delivery system.  
Those polymers undergo hydrolysis or enzyme digestion upon contacting with body 
fluids, and generate biocompatible and metabolizable moieties that are eventually 
removed from the body. Many reports suggest that the degradation rate of those polymers 
can be controlled by changing their molecular weight, cross-linking degree and polymer 
compositions 
[61]
.   
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2.1.2 Inorganic nanoparticles 
Drug release from biodegradable polymeric nanoparticles usually relies on the erosion of 
the carriers. The drug release usually takes place immediately upon water contaction. 
Such premature release of guest molecules sometimes presents a challenging problem. 
For example, targeted delivery of antitumor drugs and gene requires minimum release 
before nanoparticles reach the targeted cells or tissues. Such premature release is less 
likely to happen if drugs are loaded into inorganic nanoparticles.  Inorganic nanoparticles 
also possess other properties that make them promising targeted or controlled delivery 
systems. Such properties include stable structure, large surface area, rich functionality, 
tunable pore sizes, well-defined surface properties as well as good biocompatibility. 
Numerous researches have done in the development of inorganic nanoparticles drug 
carriers 
[62,63]
.  Gold and silica nanoparticles are two of the most popular inorganic 
nanoparticle drug carriers because of their low toxicity and reliable synthesis.  
2.1.2.1 Gold nanoparticles  
Gold nanoparticles (AuNPs) possess several unique features that make them ideal carriers 
for drug delivery. AuNPs are essentially inert, non-toxic 
[64]
, and can be produced reliably 
with particle sizes ranging from 1 nm to 150 nm 
[64-66]
.  The surface of AuNPs is readily 
to be modified by functional groups such as thiols and amines 
[64]
. The optical and 
electronic features of AuNPs can be applied to control drug release 
[67]
.  Various moieties 
such as oligonucleotides, proteins, and antibodies and be linked to AuNPs and deliveried 
into living cells 
[68-70]
. The release of those loaded moieties could be triggered by internal 
changes in pH, glutathione levels 
[71,72]
, or external exertion of light 
[73]
.  Such 
applications in drug delivery represent a new direction of AuNPs research that greatly 
deviates from the more established use of AuNPs as labels for electron microscopy 
[74]
.  
Gold nanoparticles can be prepared by various techniques such as citrate reduction, 
Brust-Schiffrin method and microemulsion. 
Citrate reduction is the most conventional methods to synthesize AuNPs.  It applies citric 
acid to reduce HAuCl4 in water. The ratio of the HAuCl4, reducing agents can be varied 
to obtain AuNPs of with different particle sizes (between 20 and 150 nm). This method is 
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often used when a loose shell of ligands around the gold core is required to prepare 
modified AuNPs 
[65]
.  
Brust-Schiffrin method allows the facile synthesis of stable AuNPs of small size (1.5-
5nm) and narrow size distribution. The obtained AuNPs can be repeatedly isolated and 
re-dissolved in common organic solvents without irreversible aggregation. Furthermore, 
the AnNPs can also be functionalized just as stable organic and molecular compounds. 
The technique uses the thiol ligands that strongly bind gold due to the soft character of 
both Au and sulfur. Specifically, AuCl4 is transferred to toluene using 
tetraoctylammonium bromide as the phase-transfer reagent and reduced by NaBH4 in the 
presence of dodecanethiol 
[75]
.  The sizes of particles are in the range 1-3 nm. Larger 
thiol/gold mole ratios or faster reducing agents addition gives smaller particle sizes. 
The use of microemulsion technique involves a two-phase system with a surfactant that 
causes the formation of the microemulsion. The microemulsion helps to maintaining a 
favorable microenvironment for the AnNPs synthesis and extract metal ions from 
aqueous phase to organic phase. An example of this method is the synthesis of 
dodecanethiol capped AuNPs within a microemulsion of diethyl ether/aerosol-OT/water. 
The reduction of gold chloride in the presence of dodecanethiol results in the formation 
of stable, organically soluble nanoparticles of 4nm average diameter 
[76]
.   
2.1.2.2 Silica nanoparticles  
Silica nanoparticles are comprised of a honeycomb-like porous structure with hundreds 
of empty channels that are able to encapsulate relatively large amounts of bioactive 
molecules. Silica nanoparticles possess several unique properties, such as high surface 
area, large pore volume, tunable pore size with a narrow size distribution, and good 
stability. Such properties make them promising carriers for controlled or targeted drug 
delivery. 
The synthesis of silica nanoparticles is developed on the technique found by Mobil 
researchers. Specifically, tetraethyl orthosilicate (TEOS) is used as a silica source, a 
cationic surfactant  cetyltrimethylammonium bromide (CTAB) is used as a structure 
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directing agent, water is used as solvent, and sodium hydroxide is used as catalyst 
[77]
. 
The template surfactant (CTAB) is removed by solvent extraction to generate pores. This 
technique is base on the formation of liquid-crystalline mesophases of surfactants that 
serve as templates for the in situ polymerization of orthosilicic acid. The synthesis can be 
performed either in acidic or basic conditions, and the source of silica can be fumed 
silica, sodium silicate, or tetra-alkyl oxide of silane 
[62]
.  
Surface modification can impart silica nanoparticles with special properties to meet 
different requirements. Co-condensation and grafting 
[78]
 are two most applied 
modification methods for silica nanoparticles. In co-condensation method, 
organoalkoxysilane is introduced to the basic, aqueous CTAB and TEOS solution, and 
surface modified silica nanoparticles are directly synthesized. Grafting is commonly 
carried out by silylating free (≡SiOH) and geminal silanol (=Si(OH)2) groups on the 
surface of silica nanoparticles. This reaction is performed on surfactant-removed 
mesoporous silica in nonpolar anhydrous solvents to avoid a reaction of the organosilanes 
with anything but the silica material. 
2.1.2.3 Application of inorganic nanoparticles 
2.1.2.3.1 Gold nanoparticles 
Glutathione mediated delivery: The intracellular glutathione concentration is 
substantially higher than its extracellular levels 
[79-82]
.  The phenomenon provides a 
mechanism for selective intracellular drug delivery with AuNPs.  The AuNPs carrier is 
modified by a mixed monolayer composed of cationic ligands and model drugs. The 
ligands generate a cationic surface to enhance cellular uptake. Once the carriers entered 
cells, the concentrated glutathione in the cells would replace the loaded drugs from the 
AuNPs 
[83]
.  
Through sulfur-gold bonds, 6-mercaptopurine-9-β-D-ribofuranoside (6-MPR) can be 
loaded to the surfaces of AuNPs 
[84]
. Compared to free drug, the anti-proliferative effect 
of 6-MPR is significantly enhanced by its AuNPs carrier. The enhanced anti-proliferation 
effect can be explained by two cooperative mechanisms. First, 6-MPR loaded AuNPs 
could be endocytosed and transferred to the lysosomes, the sulfur-gold bonds are severed 
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in the acidic environment of lysosomes. Second, sulfur containing biomolecules such as 
glutathione and cysteine, can simply replace 6-MPR from the Au surface. 
AuNPs can also be modified with multiple moieties. A targeted AuNPs is obtained by 
functionalizing AuNPs with 1) cyclodextrin (SH-CD) to encapsulate drugs, 2) anti-
epidermal growth factor receptor (anti-EGFR) antibody as a targeting moiety, and 3) 
PEG as an anti-fouling shell. Rhodamine B is used as model drug 
[85]
. Compared with 
regular cell lines, internalization and drug release of this AuNPs are faster in cells with 
higher glutathione concentration and EGFR surface expression.  
PEG mediated delivery: Polyethylene glycol (PEG) has been approved for human 
intravenous application. The surface of PEG modified AuNPs has a PEG layer that 
inhibits colloid aggregation 
[86,87]
 and resists protein adsorption in physiological 
conditions 
[88,89]
. Drugs on the nanoparticles could be shielded from endocytosis of the 
reticuloendothelial system 
[90]
. Therefore, the circulation time of nanoparticles are 
extended. Such drug vectors can preferentially accumulate in tumor sites 
[90]
.  Tumor 
necrosis factor (TNF) is loaded into such AuNPs and the obtained TNF-PEG-AuNPs 
shows a targeted TNF delivery into solid tumors 
[91]
.  
AuNPs modified with a monolayer of folate-conjugated poly (L-aspartate-doxorubicin)-
b-poly(ethylene glycol) copolymer (Au-P(LA-DOX)-b-PEG-OH/FA) can work as a 
tumor targeted drug carrier 
[92]
. The Au-P(LA-DOX)-b-PEG-OH/FA consists of an Au 
core, a hydrophobic poly(L-aspartate-doxorubicin)  inner shell, and a hydrophilic 
poly(ethylene glycol) and folate-conjugated poly(ethylene glycol) outer shell (PEG-
OH/FA). Tumor cell endocytosis of the nanoparticles is facilitated by the folate receptors, 
are highly expressed on the surface of tumor cells. The release of doxorubicin (DOX) 
from the modified AuNPs is promoted by acidic environment in tumor cells. 
Other ligands mediated delivery: Various other ligands are also able to stabilize and 
direct AuNPs to targets. Chitosan modified AuNPs are applied to deliver insulin. This 
new system showes a significant blood glucose lowering effect and a noticeable 
improvement in the cell uptake than the oral and nasal administered insulin 
[93].
 
19 
 
Kamat’s group attached a light-sensitive and conformation-changing molecule, 
spyropyran, to surface of AuNPs. Amino acid is loaded to the nanoparticles by forming a 
complex with spyropyran. When spyropyran is irradiated by ultraviolet light, it undergoes 
a conformation change from an open form to a closed form, which triggers the release of 
amino acid 
[94]
. 
2.1.2.3.2 Silica nanoparticles 
Drugy delivery controlled by morphology: Due to the high surface areas and pore 
volumes of silica nanoparticles, guest molecules are able to be simply adsorbed on the 
porous surface or into the pores. Release of the loaded drug is controlled either by the 
size or the morphology of the pores. Silica nanoparticles with large pores (5nm) can host 
small membrane-impermeable proteins, such as cytochrome c, and release them under 
physiological conditions 
[96]
. These silica nanoparticles serve as efficient transmembrane 
carriers to deliver cytochrome c into HeLa cells.  
Drug delivery controlled by surface modification: Surface modified silica 
nanoparticles can be use for DNA delivery. Thiol groups modified silica nanoparticles 
are covalently attached to PAMAM dendrimers. The G2-PAMAM capped silica 
nanoparticles are used to complex with plasmid DNA. The complex protects the plasmid 
DNA from enzymatic cleavage. This nano gene carrier shows better transfection 
efficiency than most commercial transfection reagents 
[97]
.  
2.2 Enzyme immobilization with nanomaterials 
Biocatalysis, a green, sustainable technology for chemistry industry, commonly uses 
enzymes as highly active and selective catalysts. Most enzymes operate at mild 
temperature, neutral aqueous solutions, and in the absence of substrate functional-group 
protection 
[98]
. Additionally, enzymes catalyzed reactions generally tolerate structurally 
diverse substrates, produce highly stereo-, enantio- and regiochemically defined products, 
and usually generate waste streams suitable for municipal sewers 
[99]
. In practical 
production, an enzyme can be used alone, in combination with other enzymes, or with 
non-biological reagents. With the improvement of biotechnology such as protein 
engineering 
[100,101]
, gene synthesis, and bioinformatics tools 
[102]
, engineered enzymes 
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that meet the specific requirements of a given process can be produced on a large scale. 
Those engineered enzymes usually possess special properties such as superb stability 
against temperature or organic solvents, and ability to catalyze non-natural reactions 
[103]
. 
However, despite the fact that over 3,000 enzymes have been identified, only a little 
proportion of them is exploited for chemistry industry
 [98]
.  
The economic feasibility of an enzyme catalyzed process is determined by several major 
factors: 1) the type of enzyme to be used, 2) the stability of the selects enzymes and 3) 
the reactor and hardware configurations
 [104]
. Many expensive enzymes could not be 
applied in industry unless they were made recyclable and reusable. Although free 
enzymes can be recycled with coupled reaction and immobilized cofactor 
[105]
, those 
techniques require costly modification of current standard reactors 
[106]
. Enzyme 
immobilization may make the application of high cost enzymes in industry economically 
feasible for many reasons: 1) Immobilized enzymes are convenient to be recycled for 
continuous utilization. 2) Immobilization usually enhances enzyme stability under storage 
and operational conditions. 3) Immobilization enables enzymes to be used in a packed-
bed or fluidized-bed reactor
 [106]
. 4) Enzyme immobilization helps to reduce protein 
contamination of the product. 
Enzymes can be immobilized to a substrate via a variety of techniques such as non-
covalent adsorption, covalent attachment, polymeric entrapment and cross-linking 
[107]
. 
However, all these approaches are a compromise between maintaining high catalytic 
activity and achieving the advantages of immobilization
 [108]
.  The performance of 
immobilized enzymes depends on the properties of supporting materials such as material 
composition and structure. Nonporous substrates have minimum diffusion limitation, but 
their enzyme loadings are usually low. On the other hand, porous materials are 
characterized by higher enzyme loading, but greater diffusion limitation than nonporous 
enzyme support. The large surface area and small size of nanomaterials make them ideal 
enzyme supporters for bio-catalysis. The larger surface area leads to higher enzyme 
loading per unit mass, and the small size shortens diffusion path of reactants and leads to 
much reduced mass-transfer resistance 
[109]
. Moreover, Attaching to nanomaterials can 
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significantly stabilize some free enzymes 
[108,109]
.  The supporting nanomaterials for 
enzyme immobilization include nanoparticles and nanowires/nanotubes. 
2.2.1 Application of nanoparticles for enzyme immobilization 
Nanoparticles made from numerous inorganic materials, such as calcium carbonate, 
Fe3O4, and silica, have been applied to support enzyme immobilization. Calcium 
carbonate nanoparticles are exploited to immobilize glucose oxidase to detect glucose. 
Immobilized glucose oxidase exhibit a marked improvement in thermal stability 
compared to other inorganic glucose oxidase host matrixes. The system shows a rapid 
response, a wide linear range, a high sensitivity, as well as a good operational and storage 
stability 
[110]
. Fe3O4 magnetic nanoparticles are used to immobilize yeast alcohol 
dehydrogenase (YADH) via covalent binding. Compared to the free enzyme, the 
immobilized enzyme retains 60% activity and shows a great increase in stability and 
activity 
[111]
. Cofactor NAD(H) covalently attached to silica nanoparticles is able to 
coordinate with other enzymes immobilized on the same particles. Such coordination 
enables multistep bio-transformations 
[112]
. Specifically, silica nanoparticle-attached 
glutamate dehydrogenase (GLDH), lactate dehydrogenase (LDH) and NAD(H) are 
applied to catalyze the coupled reactions for production of α-ketoglutarate and lactate 
with the cofactor regenerated within the reaction cycle. The nanoparticles enzyme 
carriers provide effective interactions among the catalytic components, and thus realize a 
dynamic shuttling of the particle-supported cofactor between the two enzymes to keep the 
reaction cycles continuing. 
Despite the popularity of nanoparticle based enzyme supporters, their indigenous 
disadvantages limit their broad application: due to their small size and high surface 
energy, they are unstable over long storage. Moreover, if dispersed, those nanoparticles 
are impossible to be recycled with current standard reactors 
[113]
.  
2.2.2 Application of nanorods for enzyme immobilization 
Nanorods are nano sized rods/wires/ tubes manufactured or grown onto the surface of 
their substrates. The premise of using nanrodss for immobilization is to reduce diffusion 
limitations and maximize the functional surface area to increase enzyme loading 
[114]
.   
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Glucose oxidase (GOx) can be immobilized to ZnO nanotubes
[115]
 or gold nanorods
[115]
  
to work as a glucose sensor. The substrates of such nanorods/nanotubes can be metallic 
or cellulose acetate membrane. Immobilization does not alter the native conformation and 
activity of GOx. The obtained glucose sensor shows superb sensitivity, linear range, anti-
interference ability and long-term stability. 
Alcohol-dehydrogenase (ADH) functionalized nanowires can work as a 
bioelectrocatalytic system for enzymatic transformations of ethanol. Specifically, ADH is 
functionalized to three-segment (Ni-Au-Ni) nanowires, the nanowires are integrated with 
carbon nanotubes (CNT) modified amperometric to form a microsystem. The presence of 
the ethanol substrate and NAD
+
 cofactor will switch the orientation of the nanowires 
from vertical to horizontal and bring ADH and its NADH product to the CNT film. This 
promotes the electrocatalytic detection of NADH and the regeneration of NAD
+
 essential 
for enabling the continuous bioelectrocatalytic turnover. Such microsystem has been used 
to develop a biosensor for simultaneous detection of methanol and ethanol 
[116]
. 
2.3 Summary 
Despite their strong activities, high catalytic specificities, and commercial availability, 
proteins and enzymes still face several major barriers in their way to broad industrial 
application. The most significant one of the barriers is their instability.   
Loading or immobilizing proteins or enzymes into nanoparticles can protect them from 
premature degradation, enhance their stability and prolong their activities. Lots of 
protein-loaded nanoparticles have been commercialized for pharmaceutical application. 
As for the biocatalysis, the small particle size of emzyme functionalized nanoparticles 
brings a problem of efficient enzyme recycling with current standard reactors. Compared 
to other enzyme immobilization supporters, nanorods not only keep the advantages of 
nanoparticles as enzyme supports, but also economically feasible for recycling in 
standard reactors. Such technology is a promising method to produce stable and high 
efficient biocatalysts. 
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Chapter 3  
Materials and Experimental Methods 
3.1 Materials  
2-Aminoethyl methacrylate hydrochloride (AEMA), 2,2-Dimethoxy-2-
Phenylacetophenone (DMPA), 2-Hydroxyethyl Methacrylate (HEMA), 4-Nitrophenyl 
acetate, Acetic acid (≥99.5%), Albumin bovine serum, Ammonium hydroxide (A.C.S 
reagent, NH3 content 28-30%), Calcium chloride (93.0%), Carbonic anhydrase (from 
bovine erythrocytes), Chitosan (medium molecular weight), Cyclohexane (A.C.S grade, 
≥99%), Dimethyl Sulfoxide (DMSO, ≥99.9%), ethylene glycol dimethylacrylate 
(EGDMA), Gelatin (from porcine skin, type A), Glutaraldehyde solution, Grade I (25%), 
Gold (III) chloride trihydrate, Hydrochloric acid (36.5-38.0%), Heparin disaccharide I-A 
sodium salt, Hexamethylenetetramine, Hexyl alcohol (regent grade, 98%), Hydrochloric 
acid (36.5-38.0%), Phenolphthalein, SigmaFast protease inhibitor tablets, Sodium 
Chloride, Sodium citrate tribasic dihydrate (ACS reagent 99.0%), Sodium hydroxide, 
Sodium tripolyphosphate (85%), Tetraethyl orthosilicate (regent grade, 98%), 
Tris(hydroxymethyl) aminomethane (Tris), Triton X100, zinc acetate dehydrate (99.9%), 
zinc nitrate hexahydrate (98%)  were purchased from Sigma-Aldrich. Acetone (regent 
grade) and Ethyl alcohol (95%) was obtained from Caledon (ON, Canada) and 
Commercial Alcohols (ON, Canada) respectively. BCA protein assay kit was bought 
from iNtRON Biotechnology (South Korea), Omnipur PBS tablet (phosphate buffer 
saline, pH7.3-7.5) was purchased from EMD Chemical (USA). Recombinant human 
basic fibroblast growth factor (bFGF) was purchased from Invitrogen (CA, USA). 
Human bFGF ELISA kit was obtained from RayBiotech Inc. (GA, USA). 
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3.2 Experimental Methods   
3.2.1 Synthesis of gold nanoparticles  
12 mg Gold (III) chloride trihydrate was dissolved in 50 mL distilled water to reach a 
concentration of 0.1 mmol/L. 1.14 g Sodium citrate tribasic dihydrate was dissolved in 
100 mL of distilled water with the concentration of 38.8 mmol/L. Gold (III) chloride 
trihydrate solution was heated to boil under constant stirring. 5.5 mL Sodium citrate 
tribasic solution was added to the boiling Gold (III) chloride trihydrate solution, stirring 
was continued for 15 mins. The color of the solution changed from yellow to dark blue to 
purple and finally to red. Once the color turned to red, heating was stopped and the 
solution was cooled down to room temperature, and 0.1 mM gold nanoparticles (AuNP) 
were thus obtained.  
3.2.2 Labelling BSA with gold nanopartilces 
To label bovine serum albumin (BSA) with AuNP, the least BSA to AuNP ratio which 
keeps the AuNP resistant to aggregration should be found first. Different amount of 0.4 
mg/mL BSA solution were mixed with 2 mL AuNP and diluted to 5 mL to make series 
solutions with different BSA to AuNP ratio. The series solutions were incubated in dark 
for 30 mins. Afterward, 1 mL of 2 mol/L sodium chloride solution was added to the 
series solutions and the mixtures were store at room temperature for 1 hour. After 1 hour, 
the color change of the series solutions was recorded. Optimal BSA to AuNP ratio was 
determined by selecting the lowest ratio that can keep the color (surface plasma 
resonance) of AuNP consistent.   
According to the optimal ratio of 40 µg BSA to 1 mL AuNP, the labeling was carried out 
by dissolving 10 mg BSA in 25 mL distilled water to the concentration of 0.4 mg/mL. 0.1 
mL BSA solution was mixed with 1 mL AuNP and the mixture was incubated in 
darkness for 30 mins. The UV-Vis absorptions of BSA, AuNP, AuNP labeled BSA 
(BSA-AuNP) and BSA-AuNP released from gelatin microspheres were scanned from 
400 nm to 800 nm. 
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3.2.3 Characterization of AuNP labeled BSA (BSA-AuNP) 
3.2.3.1 UV-Vis spectrum of BSA-AuNP 
Different amount of 0.4 mg/mL BSA solution were mixed with 2 mL AuNP and diluted 
to 5 mL to make series of BSA-AuNP solutions with different BSA to AuNP ratios. After 
incubation in dark for 30 mins, their UV-Vis absorption was scanned from 200 nm to 800 
nm. 
3.2.3.2 Calibration curve of BSA-AuNP 
1 mmol/L BSA-AuNP was diluted to 0.5, 0.25, 0.125, 0.0625 and 0.03125 mmol/L series 
solutions with water.  UV spectra of the series solutions were obtained by scanning them 
from 200 nm to 800 nm. Using the absorption values of series solutions at their λmax as y-
coordinates and concentrations of BSA-AuNP as x-coordinates, linear regression was 
made to get equation of the calibration curve. 
3.2.3.3 TEM observation of BSA-AuNP 
The geometrical characteristics of BSA-AuNP were examined using a Phillips CM10 
transmission electronic microscopy (TEM).  TEM samples were prepared by placing a 
drop of BSA-AuNP solution directly on a carbon coated copper grid (200 mesh). The 
sample was air dried overnight before TEM examination.  
3.2.3.4 FTIR spectra of BSA, AuNP and BSA-AuNP 
Fourier transform infrared (FTIR) was utilized to study the interaction between AuNP 
and BSA. 250 mg BSA was dissolved into 25 mL AuNP. AuNP and BSA-AuNP 
powders were obtained by lyophilization. BSA-AuNP, BSA and AuNP were scanned by 
FTIR in the range of 500–4000 cm-1 with a 1 cm-1 resolution. The instrument used air as 
background. 
3.2.3.5 Raman spectra of BSA, AuNP and BSA-AuNP 
Raman was also applied to study the interaction of AuNP with BSA. 250 mg BSA was 
dissolved into 25 mL AuNP. AuNP, BSA-AuNP powders were obtained by 
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lyophilization. BSA-AuNP, BSA and AuNP were scanned by Raman in the range of 
100–2000 cm-1 with a 2 cm-1 resolution. 
3.2.4 Incorporation of BSA-AuNP into gelatin microspheres  
1.5 g gelatin was dissolved in 15 mL distilled water to a concentration of 10% (wt/vol) at 
50°C. 3 mL span 80 was added to 150 mL liquid paraffin as the oil phase. The oil phase 
was mixed homogeneously and heated to 50°C. Different amount of glutaraldehyde (20, 
30 µL) was added into the 10% gelatin solution and stired for 30 seconds. The gelatin 
solution was slowly poured into the oil phase to form the gelatin microspheres. To 
crosslink the gelatin microspheres with glutaraldehyde, the microspheres were first 
stirred at 50°C for different time (30, 45 mins), then at room temperature till the total 
strring and reaction time reached 60 mins. After reaction, 100 mL acetone was added to 
the oil phase under vigorous stir, gelatin microspheres was dehydrated by the acetone and 
precipitated from the the oil phase. The precipitated gelatin microspheres were separated 
from solution with filter paper. The precipitate was washed with 25 mL acetone for three 
times by sonication (to re-disperse the microspheres in washing media) following 
centrifuging (5,500 rpm, 10 mins, to precipitate microspheres from washing media). The 
washed microspheres were air dried at room temperature overnight.  The process to 
produce gelatin microsphere is shown in Figure 3.1. 
 
Figure 3.1 Preparation of gelatin microspheres 
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BSA-AuNP was added to dry gelatin microspheres at a ratio of 4mL BSA-AuNP to 0.4 g 
dried gelatin microspheres. The mixture was first frozen with liquid nitrogen. Afterward, 
the frozen samples were lyophilized with a VIRTIS Sentry Freeze Dryer (SP Scientific, 
USA) overnight. In every 1 g of the obtained gelatin microspheres, there was 10 µM 
BSA-AuNP and 400 µg BSA, respectively. 
3.2.5 BSA -AuNP release from gelatin microspheres  
0.4 g BSA-AuNP loaded gelatin microspheres and 0.4 g plain gelatin microspheres were 
mixed with 40 mL deionized water to work as sample and reference. The release test was 
carried out at 37°C. At 1, 2, 3, 4, 6, 8, 12, 24 hours after the release, 1 mL release 
medium was taken out from the sample and reference and kept at 4°C. Before testing, all 
samples were first heated at 37°C to be liquefied and centrifuged at 5,000 rpm for 5 mins 
to get the supernatant. 150 µL supernatant of each sample was put into a well a 96-well 
plate. The absorption of the samples was tested with a plate reader at 525 nm. Using the 
percentage of released BSA-AuNP to its initial drug load as y-coordinates, and release 
time as x-coordinates, BSA-AuNP release profiles from different carriers were drawn.  
3.2.6 Gelatin dissolution from gelatin microspheres  
Plain gelatin samples taken at Part 3.2.5 were used to test the gelatin dissolution in the 
release media. Before testing, all samples were first taken from 4°C refrigerator and 
heated at 37°C to be liquefied. Afterwards, the samples were centrifuged at 5,000 rpm for 
5 mins to get the supernatant. 25 µL supernatant of each sample was diluted 50 times 
with deionized water. Protein concentration in the diluted samples was tested with a BCA 
protein assay kit. Using gelatin concentrations as y-coordinate and release time as x-
coordinate, dissolution profile of gelatin microspheres was drawn. 
3.2.7 Synthesis of ZnO nanorods (Contributed by Dr. Yi Cheng) 
Seed solution was made by dissolving zinc acetate in 100 mL ethanol to a concentration 
of 0.01 mol/L. The seed solution was dropped on glass chips and the seed layer was 
heated at 90°C for 1 hour. After heating, the ZnO seeds coated glass chip was immersed 
in 200 mL aqueous solution containing 0.025 mol/L zinc nitrate and 0.025 mol/L 
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hexamethylenetetramine (HMTA) and the solution was heated at 90°C for another 3 h. 
The final grown film was rinsed with deionized water and dried at room temperature.   
3.2.8 Immobilization of CA on ZnO nanorods 
A reversible denaturation process 
[1]
 was applied to immobilize carbonic anhydrase (CA) 
on the ZnO nanorods.  CA was dissolved in Tris-HCl buffer (0.05 mol/L) to the 
concentration of 1.25 mg/mL. The solution was first treated at 60°C for 30 mins, 
afterwards, one 2.2×2.2 cm glass chip grown with ZnO nanorods was immersed into 3 
mL pretreated CA solution and incubate together at 60°C for predetermined time. After 
the incubation, the mixture was removed to 4°C and incubated for another 24 hours to get 
the CA immobilized ZnO nanorods. The ZnO nanorods chip was removed from the 
solution and rinsed with 1mL Tris-HCl buffer (pH 8.0, 0.05 mol/L) for 3 times. 
3.2.9 Characterization of ZnO and CA-ZnO 
The morphology of the aligned ZnO nanorods was studied by Hitachi 3400S Scanning 
Electron Microscopy (SEM).  (Contributed by Dr. Yi Cheng) 
Fourier transform infrared (FTIR) was utilized to study the interaction between ZnO and 
CA. 10 mg CA was first dissolved into 3 mL pH 8.0 Tris-HCl buffer (0.05 mol/L), 
aftwewards, 10 mg ZnO nanorods were mixed with the CA solution and the mixture was 
lyophilized. CA, ZnO nanorods and ZnO nanorods immobilized with CA (CA-ZnO) 
scanned by FTIR in the range of 750–4000 cm-1 with a 1 cm-1 resolution. The instrument 
used air as background. 
3.2.10 Activity analysis of immobilized CA  
CA concentration was determined by measuring its absorbance at 280 nm. An extinction 
coefficient of 1.83 (mg/mL protein)
-1
 cm
-1
 was used to relate the absorption value to CA 
concentration 
[1]
. 
The activity of immobilized CA was analyzed by measuring the reaction speed of CA 
catalyzed 4-nitrophenyl acetate hydrolysis
 [2]
. The hydrolysis of 4-nitrophenyl was 
measured by monitoring the appearance of 4-nitrophenolate anion at 410 nm. More 
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specifically, 4-nitrophenyl acetate was dissolved in acetonitrile to get a 0.005 mol/L stock 
solution. Assay solution was made by diluting stock solution with water at ratio of 3/17 
(v/v). CA immobilized ZnO chip was added to the assay solution. At predetermined time, 
the absorption of the assay solution was measured at 410 nm.       
3.2.11 Application of  immobilized CA for CO2 capture 
CO2 saturated water was first made by pumping CO2 into deionized water till the pH 
value of the deionized water gets stable at around 3.9. Immobilized CA was immersed 
into 100 mL of the CO2 saturated water as the tested sample, another 100 mL of the same 
CO2 saturated water was used as reference. CO2 was continuously pumped into the two 
solutions. The experimental setup is shown in Figure 3.2.  
 
Figure 3.2 Experimental setup for applying immobilized CA in CO2 capture 
At predetermined time, 10 mL sample was taken out from each solution and the H2CO3 in 
each sample was determined by titrating with 0.05 mol/L NaOH. 0.5% phenolphthalein 
ethanol solution was applied as the titration end point indicator. Comparing with the 
reference, the excess H2CO3 in the sample was the CO2 sequestrated by the CA catalyzed 
CO2 hydration. 
3.2.12 Synthesis of bFGF loaded nanoparticles 
3.2.12.1 Synthesis of bFGF loaded chitosan nanoparticles 
Chitosan was first dissolved in 0.4% acetic acid water solution to reach a concentration of 
0.5% (wt/vol). bFGF solution (containing 1μg bFGF and 5 μg Heparin) was first added to 
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10 mL chitosan solution with stirring for 5 mins. Afterward, 10 mL 0.25% sodium 
tripolyphosphate (TPP) solution (wt/vol) was added following the bFGF solution 
dropwise under constant stirring. After 20 mins, the mixture was centrifuged at 8,500 rpm 
for 10 mins to precipitate nanoparticles. The precipitates was washed with 10 mL water 
for three times by a brief sonication (to re-disperse the nanoparticles in washing media) - 
centrifuging (8,500 rpm, 10 mins, to precipitate nanoparticles from washing media). 
After washing with water, the nanoparticles were washed with 20 mL ethyl alcohol once 
with the same method and the final bFGF nanoparticles were dried at 4°C. The 
illustration of the process is shown in Figure 3.3 
[3]
. 
 
Figure 3.3 Synthesis of chitosan nanoparticles 
3.2.12.2 Synthesis of bFGF loaded silica nanoparticles  
6.25 μL acetic acid was mixed with 100 mL distilled water to form a pH4 acidic solution. 
7.5 mL cyclohexane, 1.8 mL hexyl alcohol and 1.8 mL Triton X100 were mixed 
homogeneously as oil phase. Under constant stirring, 0.5 mL pH4 acidic solution was 
added to the oil phase first. 15 mins later, 100 μL tetraethyl orthosilicate (TEOS) was 
added as silica precursor. The mixture was stirred for 60 mins before 60 μL ammonium 
hydroxide was added as catalyst of TEOS hydrolysis and condensation. bFGF solution 
(containing 1 μg bFGF and 5 μg Heparin) was added to the solution 10 mins after the 
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induction of ammonium hydroxide. The final mixture then underwent constant stirring 
for another 24 hours.  
 
Figure 3.4 Reactions of TEOS that form silica particles 
 
Figure 3.5 Synthesis of silica nanoparticles 
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To separate the silica nanoparticles, 25 mL acetone was added to the mixture to break the 
emulsion and silica nanoparticles were precipitated by centrifugation (8,500 rpm, 10 
mins). The precipitant was washed with 20 mL ethyl alcohol / acetone (50/50) for three 
times by first sonication (to re-dis perse the nanoparticles in washing media) and then 
centrifuging (8,500 rpm, 10 mins, to precipitate nanoparticles from washing media).  
The final bFGF nanoparticles were dried at 4°C. The reactions of TEOS that forms silica 
nanoparticles are shown in Figure 3.4
[4]
, and the illustration of silica nanoparticle 
systhesis is shown in Figure 3.5. 
3.2.13 Characterization of bFGF loaded nanoparticles 
The geometrical characteristics of chitosan and silica nanoparticles were examined using 
Phillips CM10 transmission electronic microscopy (TEM). TEM samples were prepared 
by placing a drop of nanoparticles-acetone suspension directly on a carbon coated copper 
grid (200 mesh). The sample was dried before TEM examination.  
3.2.14 Incorporation of nanoparticles into HEMA hydrogel 
30 mg AEMA and 15 mg DMPA were dissolved in 100 μL DMSO respectively. The 
above AEMA and DMPA solutions were mixed homogeneously with 3 mL HEMA, 1 
mL DMSO and 6 μL EGDMA as hydrogel presursor. To get the nanoparticle-HEMA 
hydrogel composite, 20 mg chitosan nanopartilces or 5 mg silica nanoparticles was added 
to 1 mL of the hydrogel presursor. The nanoprticle-hydrogel presursor was sonicated for 
2 mins to resuspend the nanoparticles in the hydrogel precursor. Afterwards, nitrogen gas 
was pumped into sonicated mixture for 10 mins to saturate it with this inert gas. The 
nitrogen saturated mixture was dropped into the molds attached on cover glasses, and 
radiated under UV at 325 nm for 20 mins and for photopolymerization. The resultant 
nanoparticle-HEMA hydrogel composites were immersed in 95% overnight and peered 
off from the molds the next day. The process of photopolymerization of HEMA hydrogel 
is shown in Figure 3.6. 
41 
 
 
Figure 3.6 Reactions of photopolymerization of HEMA hydrogel 
3.2.15 bFGF stability in release medium  
Release medium was prepared by dissolving one SigmaFast protease inhibitor tablet into 
100mL pH7.4 phosphate buffer solution. The stability tests of bFGF in release media was 
carried out by adding 500 μL bFGF standard solution (10,000 pg/mL) into 12.5 mL 
release medium.  The test was performed at 4°C without agitation. At predetermined time 
points, 0.4mL sample was taken and stored at -20°C. bFGF concentration in the samples 
were quantified by enzyme linked immunosorbent assay (ELISA) analysis.  
3.2.16 bFGF release from nanoparticles and nanocomposites  
Release medium was prepared by dissolving one SigmaFast protease inhibitor tablet into 
100 mL pH7.4 phosphate buffer solution. Release test was carried out in 12.5 mL release 
medium at 4°C without agitation. Dry nanoparticles (20 mg for chitosan and 5 mg for 
silica) and one piece of nanopariticle-HEMA hydrogel were added to the release medium. 
At appropriate time points, 0.4 mL sample was taken and stored at -20°C. bFGF 
concentration in the samples were quantified by ELISA analysis. 
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Chapter 4  
Delivery of Gold Nanoparticles Labeled Protein 
Gold nanoparticles (AuNP) possess several unique properties that make them a promising 
protein label for the development of a colorimetric protein assay method. First, AuNP 
show strong and stable red color because of their size-dependent surface plasmon 
resonance 
[10]
.  Second, the surface of AuNP can be modified and stabilized with a variety 
of ligands available in proteins, such as thiols, disulfides, phosphine, amine, and 
carboxylate 
[11]
. Those ligands, especially those with sulfer atoms, are able to interact 
with gold in a way like covalent linking.  
Colorimetric protein assay is a seires of low cost, reliable and broadly applied standard 
protein quantification methods.  Among them, Biuret, Bradford and Bicinchoninic acid 
assay (BCA) methods are the most applied ones. The accuracy of colorimetric protein 
assay is not independent of the sampl properties and environmental factors. Biuret 
method is influenced by protein purity and association state 
[2]
; the analytical results of 
Bradford method vary according to the molecular weight 
[3]
 and structure 
[4,5]
 of target 
protein; and the BCA method is prone to the interference of a wide variety of substances 
such as glucose 
[6]
, fructose, lactose 
[7]
, dithiothreitol, glutathione and mercaptoethanol 
[8,9]
.  
The availability of multiple protein binding sites on AuNP and the strong nature of those 
interactions might produce a protein-AuNP complex with stable particle size. The 
protein-AuNP complex could be inert to the factors that interfere with the accuracy of 
other colorimetric protein assay method. The stable protein-AuNP complex could 
generate a steady surface plasma resonance that could be easily detected and utilized to 
quantify protein-AuNP concentration.  
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4.1 Results and Discussion 
4.1.1 Labeling BSA with gold nanopartilces (AuNP) 
The color change of series sample solutions with different BSA to AuNP ratios is shown 
in Figure 4.1 and Table 4.1. 
 
Figure 4.1 Change of BSA coated AuNP’s surface plasmon resonance (SPR) 
absorption when contacting with sodium chloride (From left to right: BSA to AuNP 
ratios are 50, 20, 0 µg/mL; aggregation of gold nanoparticles increases) 
AuNP is stabilized by electrostatic stabilization which arises from a mutual repulsion 
between neighboring AuNP that occurs as a result of the negative surface charge of the 
citrate layer 
[10]
.  Once exposed to salt (sodium chloride, for example), the repulsive 
interaction is screened and colloid aggregation is triggered 
[11]
. Based on their size-
dependent surface plasmon resonance (SPR) absorption, AuNP demonstrates a color shift 
from red to blue with increased aggregation, which can be seen in Figure 4.1. The 
absorption of the BSA on the citrate-coated AuNP further stabilizes the colloidal gold 
particles against aggregation 
[10]
. Once in contact with salt, the partial coated AuNP is 
aggregated at a lower level and shows a purple color, the totally coated AuNP keeps 
stable and no change in their surface plasmon resonance is observed. 
Table 4.1 Optimization the ratio of BSA to AuNP (1 mmol/L) 
BSA / AuNP (µg/mL) 0 2 8 20 40 50 
BSA / AuNP (µg/umol) 0 2 8 20 40 50 
0.4mg/mL BSA added (µL) 0 10 40 100 200 250 
Au NPs added (mL) 2 2 2 2 2 2 
Water added to (mL) 5 5 5 5 5 5 
Color change after 24 h Blue Blue Purple Purple Red Red 
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From Table 4.1, one can observe that when using more than 40 µg BSA in 1 mL of 
AuNP, the color (which represents the surface plasma resonance of gold nanoparticles) of 
AuNP solutions remains consistent. The consistent color suggests that AuNP is protected 
from aggregation. To increase the sensitivity of the testing, AuNP needs to be coated with 
the minimum amount of BSA so that a fixed amount of AuNP can be used to test as little 
BSA as possible. According to the results in table 4.1, at ratio of 40 µg BSA to 1 mL 1 
mmol/L AuNP, AuNP labeled BSA (BSA-AuNP) can obtain a stable signal that ensures 
the highest sensitivity. At the minimum ratio of 40 µg BSA to 1 mL 1mmol/L AuNP, 
AuNP label generates a stable, repeatable and reliable UV-Vis absorption with a λmax at 
525 nm.    
4.1.2 UV-Vis spectra of BSA-AuNP 
UV-Vis spectra of samples with various AuNP to BSA ratio are shown in Figure 4.2 and 
Figure 4.3. The maximum absorption of all BSA-AuNP is at 525 nm. All the spectra 
show a similar shape to the bare AuNP, which indicates that when BSA to AuNP 
(1mmol/L) ratio is in the range of 0-50 µg/mL (weight/volume), BSA coating does not 
alter the absorption pattern AuNP. 
 
Figure 4.2 UV-Vis spectra of samples with BSA/Au NPs ratios of 0, 2, 8, 20, 40 and 
50 
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Figure 4.3 UV-Vis spectra of BSA, AuNP, BSA-AuNP and BSA-AuNP released from 
gelatin microspheres 
At the range of 400-800 nm, BSA does not have UV-Vis absorption, AuNP and BSA-
AuNP have similar absorption peak and λmax. Due to the absorption of dissolved gelatin, 
the spectrum of BSA-AuNP released from gelatin microsphere is slightly different that of 
BSA-AuNP; however, they share the same λmax. Due to the fact that BSA-AuNP can 
provide a signal independent of BSA concentration and the gelatin microsphere 
loading/releasing process, AuNP can be applied in this research as a stable and repeatable 
protein label. 
4.1.3 Calibration curve of BSA-AuNP 
The UV-Vis absorption of the series BSA-AuNP is shown in Figure 4.4. Within the 
concentration range of 0.03125 mM - 0.5 mM, the λmax keeps constant. Using the 
absorption value of a series of solutions at 525nm as y-coordinate and concentration of 
AuNP in BSA-AuNP as x-coordinate, linear regression is carried out and the equation of 
the calibration curve is A = 1.15537C – 0.01244, with r2 of 0.99776.  
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Figure 4.4 UV-Vis spectra of series BSA-AuNP with different AuNP concentrations 
With a fixed ratio of BSA to AuNP, we can establish a quantitative relation of BSA 
concentration to the absorption of AuNP. From the fact that the optimal ratio of BSA to 
AuNP is 40 µg BSA to 1 mL AuNP (1 mmol/L), and that the detection limit of AuNP is 
0.03125 mmol/L, we can obtain a detection limit of BSA using AuNP as label is 1.25 
µg/mL.  
4.1.4 TEM observation of BSA-AuNP 
TEM micrograph of gold nanoparticles is shown in Figure 4.5. The nanoparticles are 
ideal spheres with a particle size of 15±3.5 nm and a homogeneous particle size 
distribution.  The TEM micrograph of BSA-AuNP does not show any difference from 
that of the bare AuNP. 
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Figure 4.5 TEM micrograph of BSA-AuNP 
4.1.5 FTIR spectra of BSA, AuNP and BSA-AuNP 
Figure 4.6 shows the FTIR spectra of AuNP, BSA and BSA-AuNP.  
 
Figure 4.6 FTIR spectra of BSA, AuNP and BSA-AuNP 
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In all the three spectra, the wide band stretching from 3100 cm
-1
 to 3400 cm
-1
 is the O-H 
and N-H stretching band. On the low wavenumber side of the O-H and N-H stretching 
band in the spectrum of BSA and BSA-AuNP, there are some broad bands of medium 
intensity. These are overtone and combination bands of lower wavenumber C-C 
stretching and C-H bending vibration. These features are quite common in the spectra of 
carboxyl group, which are abundant in BSA because of the large amount of aspartic and 
glutamic residues in BSA molecule.  
In the spectra of BSA and BSA-AuNP, the prominent bands at 1660 cm
-1
 can be assigned 
to the C=O stretch of amide bonds in BSA. At the wavenumber of 1530 cm
-1
, there is 
strong band in the spectrum of BSA and a visible shoulder at the spectrum of  BSA-
AuNP. It is the result of in plane bend of N-H in secondary amides. The significant peak 
at 1590 cm
-1 
and 1400 cm
-1
 in the spectrum of BSA-AuNP and AuNP are attributed to the 
asymmetric and symmetric stretch of the carboxyl group in sodium citrate. The structure 
of sodium citrate tribasic can be seen in Figure 4.7.   
 
Figure 4.7 Structure of sodium citrate tribasic 
In the spectrum of BSA, the band at 1450 cm
-1 
is caused by the C-N stretch of BSA. In all 
the spectra, the bands at 1250 cm
-1 
with medium intensity can be assigned to the C-O 
stretch of the carbonyl group in sodium citrate and BSA. In the spectra of BSA-AuNP 
and AuNP, the bands at (1) 1100 cm
-1
, (2) 900 cm
-1
, (3) 840 cm
-1
, and (4) 620 cm
-1 
originates from the tertiary alcohol of sodium citrate tribasic. Those bands can be 
assigned to (1) the C-C-O asymmetric stretch, (2) CH2-C-CH2 stretch, (3) C-C-O 
symmetric stretch and (4) O-H out of plane bending, respectively 
[12]
.  
4.1.6 Raman spectra of BSA, AuNP and BSA-AuNP 
Raman spectra of AuNP, BSA and BSA-AuNP are shown in Figure 4.8.  
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Figure 4.8 Raman spectra of BSA, AuNP and BSA-AuNP 
In the spectrum of BSA, the amide-I vibration at 1665 cm
-1
 arises mainly from the ν-C=O 
stretching vibration. The band in the range of 1440–1480 cm-1 is caused by the C-H3 and 
C-H2 deformation vibrations from the side chains of different amino acids. The amide-III 
is the combination of the NH bending and C-C stretching vibration in the region 1200-
1350 cm
-1
 and skeletal stretching region near 850-1000 cm
-1 [13]
.  The bands around 1000 
and 1030 cm
-1
 are due to the out-of-phase stretching of benzene and pyrrole residues 
[14]
. 
The disulfide stretching vibration of solid BSA is represented by the band at 500 cm
-1 [15]
. 
Significant differences can be observed between the two Raman spectra of BSA and BSA 
adsorbed on gold nanoparticles. In the spectra of AuNP and BSA-AuNP, the bands at 
1590-1600 cm
-1
 and 1420-1440 cm
-1
 can be assigned to the C=O stretching of 
carboxylate and C-H2 deformation vibration. The bands at 1320 cm
-1
 and 960 cm
-1 
in the 
spectrum of AuNP are generated from the carboxylate and skeletal stretching of sodium 
citrate 
[16]
.     
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Some information about the interaction of BSA to AuNP can be obtained by comparing 
the spectra of BSA and BSA-AuNP.   After combinging with AuNP, the strong amide 
band at 1530 cm
-1 
in the FTIR spectrum of BSA dissapears and merges with the band of 
carboxylate group. Additionally, in the Raman spectra of BSA and BSA-AuNP, the 
prominent amide band at 1665 cm
-1
 of BSA is absent in BSA-AuNP. Combining the two 
facts, it could be inferred that the BSA interacts with AuNP through its amide bonds. The 
amide bonds may not be the only force that binds BSA to AuNP. BSA exhibits positively 
charged amino acid, such as lysine or histidinem, and therefore could be conjugated to 
the negatively charged surface of AuNP through the electrostatic interaction 
[17]
. The 
presence of S-S stretching vibration of disulfide bridges in the spectrum of both BSA and 
BSA-AuNP is a strong indicator that the disulfide bonds remain unbroken and the BSA 
does not denature when adsorbed to AuNP.   
4.1.7 Release profiles of BSA - AuNP from gelatin microspheres 
The BSA-AuNP release profiles from gelatin microspheres synthesized with different 
amounts of crosslinker (glutaraldehyde), 20µL and 30µL, respectively, are shown in 
Figure 4.9.  
 
Figure 4.9 BSA-AuNP release profiles from gelatin microspheres synthesized with 
different amount of glutaraldehyde 
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The release of BSA-AuNP has been monitored for 12 hours. The release of BSA-AuNP 
decreases from 75% to 60% when the amount of crosslinker used in the synthesis 
increases from 20µL to 30 µL, or 1.6% (mL/g) to 2.4% (mL/g). 
Figure 4.10 shows the BSA-AuNP release profile from gelatin microspheres synthesized 
at a fixed amount of crosslinker 2.4% (mL/g) and reaction temperature (50°C); but 
different reaction time (t) of 30mins and 45mins, respectively.  
 
Figure 4.10 BSA-AuNP release profiles from gelatin microspheres synthesized with 
different amount of reaction time at 50°C  
All the microspheres allow a sustained BSA-AuNP release up to 12 hours. The release 
profiles get to a plateu phase when BSA-AuNP release reaches 60% and 50% at t =30 
mins and 45 mins, respectively. BSA release from gelatin microspheres can be thus 
detected by the SPR of gold nanoparticles. 
4.1.8 Release mechanism 
The rate-controlling mechanisms of drug release from hydrophilic matrices are polymer 
dissolution (erosion) and diffusion of drug molecules across the polymer lay 
[18]
. A semi-
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empirical equation has been used widely to differentiate the contributions of both 
mechanisms 
[19, 20]
.  
 
Where Mt is the amount of drug released at time t, M the amount of drug in dosage form, 
Qt the fraction of drug released at t, n the diffusional exponent, and k the kinetic constant. 
If diffusion dominates polymer erosion, the value of n would approach 0.5. On the other 
hand, for erosion controlled formulations, n would approach the value of 1. Under a 
mixed condition, the value of n falls in between 0.5 and 1 when both diffusion and 
erosion occurs simultaneously.  
The above formula can be transformed into the following formula. Using releasing value 
BSA-AuNP as Mt/M, we can calculate the value of k and n by linear regression.  
 
The results of the calculation and the concluded release mechanism of samples in part 
4.1.7 are listed in Table 4.2.  
Table 4.2 Release mechanism of BSA-AuNP from gelatin microspheres  
Sample n value Release mechanism 
BSA-AuNP-GM (20 µL) 0.34 Diffusion controlled release 
BSA-AuNP-GM (30 µL) 0.45 Diffusion controlled release 
BSA-AuNP-GM (30 mins) 0.23 Diffusion controlled release 
BSA-AuNP-GM (45 mins) 0.34 Diffusion controlled release 
Upon contacting with release media, the gelatin microspheres swell due to hydrolyzation, 
and generate enlarged channels for drug release. BSA-AuNP can easily pass through 
these enlarged channels and go into release media. The more crossliner used to synthesize 
the gelatin microsphere, the more porous the scaffold and the narrower the channels will 
be. Such smaller channels make the transportation of BSA-AuNP from inside 
microspheres to release media slower and harder. Additionally, prolonged reaction time 
of the crossliner with gelatin microspheres results in a gelatin scaffold with a higher 
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crosslinking level and mechanical strength. Compared with the scaffold of less reacted 
gelatin microspheres, this more crosslinked scaffold is harder to hydrolyze and less likely 
to swell in release media. The channels that BSA-AuNP need to go to release media are 
more narrow and elongated, and thus, BSA-AuNP release is slower.  
4.1.9 Degradation of gelatin microspheres 
To investigate the release mechanism of BSA-AuNP from gelatin microspheres, the 
degradation ofgelatin microsphere was studied by testing gelatin concentration in release 
medium. The profile of gelatin concentration-time is showed in Figure 4.11.  
 
Figure 4.11 Degration profile of gelatin microsphere 
Gelatin microspheres dissolve gradually. Figure 4.11 showes the concentration of gelatin 
in the release medium increases from 1 mg/mL to 4 mg/mL. Gelatin dissolution reaches 
at a plateau at the eighth hour of the release test.  Such gelatin dissolution curve is in 
coincidence with the BSA-AuNP release profiles. The results suggest AuNP is seep into 
the scaffold of gelatin microsphere during the loading process. During release, AuNP at 
the out layer of gelatin microspheres is released in a diffusion controlled pattern. At the 
same time, the gelatin scaffold undergoes degradation.  The degradation of gelatin 
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shortens the channels that in gelatin microspheres scaffold and facilitates the movement 
of AuNP from gelatin to the release media. This scaffold degradation keeps the constant 
release rate of BSA-AuNP from gelatin microsphere to release media. 
4.2 Conclusions 
A new AuNP assisted protein assay method was developed in the works introduced in 
this chapter. AuNP was used to label a model protein, BSA. FTIR and Raman spectra 
were carried out to study the interactions between BSA and AuNP. The results show that 
BSA is incorporated onto AuNP through the interaction between gold and amide 
functional groups. The surface plasma resonance (SPR) of AuNP labeled BSA (BSA-
AuNP) has been investigated, which is linearly to the AuNP concentration within the 
range of 0.03125-0.5 mmol/L. The detection limit of BSA-AuNP is 1.25 µg/mL. The 
release profile of BSA-AuNP from gelatin microspheres has been investigated through 
testing the SPR of AuNP in the term of crosslinker and reaction time. It is found that 
BSA-AuNP is released from its gelatin micro-carriers for 12 hours in a diffusion 
controlled manner. The degradation of gelatin microspheres is compatible to the diffusion 
of BSA-AuNP.  
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Chapter 5  
Enzyme Immobilization  with Nanorods for CO2 Capture 
Enzymes are highly active and selective catalysts usually applied in bio-catalysis, a green, 
sustainable and environmentally friendly technology in the chemical industry. Over 3,000 
enzymes were identified, however, only a very few of them have been employed in 
industrial scale
 [1]
. The factors that hold back the wide spread application of enzymes are 
1) the high cost of most enzymes and 2) the difficulties in recycling them from standard 
reactors 
[2]
.   
Enzyme immobilization is an economically feasible way to use pricey enzymes. 
Immobilization makes enzymes reusable for continuous utilization, enhances enzyme 
stability and enables enzymes to be used in packed-bed or fluidized-bed reactors
 [2]
. 
When using regular immobilization supporters, the process of immobilization is a 
compromise between maintaining high catalytic activity and achieving the advantages of 
immobilization
 [3]
.  Nonporous substrates have a minimum diffusion limitation while 
enzyme loadings are usually low. On the other hand, porous materials are characterized 
by higher enzyme loading, but have greater diffusion limitations than nonporous enzyme 
supporters.  
The large surface area and small size of nanomaterials make them ideal enzyme 
supporters for bio-catalysis. The large surface area leads to high enzyme loading per unit 
mass, and the small size shortens the diffusion path of reactants and leads to reduced 
mass-transfer resistance 
[4]
. Moreover, attaching free enzymes to nanomaterials 
significantly protects them from losing their activities 
[3,4]
.   
 Nanorods are a nanomaterial that can be easily separated and recycled in reactors 
without aggregation 
[5]
.  Because of the superb biosafety and biocompatibility of zinc 
oxide (ZnO), ZnO nanorods could be an ideal enzyme immobilization supporter 
[6]
.  The 
activities of immobilized enzymes are unlikely to be interfered with by the ZnO nanorods.  
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The isoelectric point (pI) of ZnO is 9.5, which is higher than most proteins’ pI. Proteins 
can be incubated together with ZnO nanorods in buffers with a pH value between the pI 
of proteins and ZnO. In such buffers, protein and ZnO are oppositely charged and the 
protein can attach to ZnO nanorods surface via electrostatic interaction. 
In this chapter, carbonic anhydrase (CA), an enzyme that is usually applied to enzyme 
electrodes 
[7]
 and carbon dioxide sequestration 
[8]
, is selected as the model enzyme. ZnO 
nanorods are used as the enzyme immobilization supporter.    
5.1 Results and Discussion 
5.1.1 Immobilization of CA on ZnO nanorods 
The UV spectra of CA water solution and 60 °C treated CA Tris-HCl buffer (pH7.5, 
pH8.0) solutions are shown in Figure 5.1.  
 
Figure 5.1 UV Spectra of CA in different immobilization buffers 
The heating (60 °C) treatment and Tris-HCl buffer do not interfere with the spectrum of 
CA. The maximum absorption of CA is at a wave length (λ) of 280 nm, where the UV 
reading is a function of the concentration of CA. The CA absorption before and after 
immobilization are collected using a UV-vis spectrometer to calculated the CA 
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immobilization ratios.  The calculated CA immobilization ratios are 0% (in water), 50% 
± 0.5 (in pH7.5 Tris-HCl buffer), and 59% ± 0.6 (in pH8.0 Tris-HCl buffer), respectively.  
According to a report 
[9]
, the reversible denaturation process makes CA immobilize onto 
the hydrophobic substrate via simple absorption. However, based on our experiment, the 
pH value played a major role in the immobilization process. CA dissolved in water could 
not immobilize onto ZnO nanorods. Meanwhile, when the pH value of immobilization 
buffer increased from 7.5 to 8.0, the immobilization ratio of CA increased from to 50% to 
about 60%. The isoelectric point (pI) of CA and ZnO are 6.7-7.9 
[11]
 and 9.5 
[12]
, 
respectively. In the pH 7.5 and pH 8.0 immobilization media, ZnO is positively charged 
whereas CA is negaitively charged. The electrostatic interaction, which is generated from 
oppositely charged CA and ZnO nanorods, may be the real force that causes the 
absorption and immobilization of free CA onto ZnO nanorods. 
5.1.2 Characterization of ZnO nanorods (Contributed by Dr. Yi Cheng) 
The top view of SEM micrograph of ZnO nanorod on a glass substrate is shown in Figure 
5.2 (a). ZnO nanrods grew densely and uniformly on the substrate surface. The average 
diameter of the ZnO nanorods is 161±10 nm. The cross-sectional SEM iamge of ZnO 
nanorod arrays is shown in Figure 5.2 (b). All nanorods are well-aligned on substrate 
surface and their average height is approximately 2 µm. 
 
 
 
 
 
Figure 5.2 SEM micrographs of ZnO nanorods. (a) Top and (b) Cross-sectional view 
FTIR spectra of ZnO, CA and CA-ZnO are shown in Figure 5.3. ZnO does not show any 
bands. The bands around 2400 cm
-1 
are the asymetric stretch of CO2. 
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Figure 5.3 FTIR spectra of ZnO, CA and CA-ZnO 
In the spectra of CA and Ca-ZnO, the wide bands stretching around 3250 cm
-1
 are the N-
H stretching band. The prominent bands at 1650 cm
-1
 can be assign to the C=O stretch of 
amide bonds in CA; the other strong bands at the wavenumber of 1540 cm
-1
 is the result 
of secondary amide N-H bending.  
ZnO does not have IR absorption. The major bands of CA and CA-ZnO are originated 
from the amide bonds of CA. Those major bands do not show significant variation after 
CA immobization. From the result, it can be concluded that chemical interactions are 
unlikely the forces that cause the CA immobilization. The FTIR analysis supports the 
hypothesis that electrostatic interaction generated from oppositively charged CA and ZnO 
results in the CA attachement on ZnO nanorods. 
5.1.3 Activity of Immobilized CA  
The UV-Vis absorption of 4-nitrophenolate anion in different samples along with time (t) 
is shown in the Figure 5.4. In all three samples, absorption intensity and time are found to 
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have a linear relationship. Liner regression is made to calculate the slopes of the UV-Vis 
absorption, which represents the speed of the hydrolysis of 4-nitrophenyl acetate. 
 
Figure 5.4 Hydrolysis of 4-nitrophenyl acetate catalyzed by different CA-ZnO 
4-nitrophenolate anion, a greenish yellow compound with a strong absorption near 
400nm, is the product of the hydrolysis of the colorless 4-nitrophenyl acetate 
[10]
, the 
reaction is shown in Fig. 5.5.   
 
Figure 5.5 CA catalyzed hydrolysis of 4-nitrophenyl acetate  
62 
 
The speed at which this hydrolysis product is produced represents the hydrolysis speed of 
4-nitrophenyl acetate 
[10]
. The faster the 4-nitrophenyl hydrolysis, the more active the 
immobilized CA would be. As shown in Figure 5.3, plain ZnO nanorods were used as the 
reference to evaluate the activity of immobilized CA on ZnO nanorods (CA-ZnO).  4-
nitrophenyl acetate underwent self- hydrolysis at a speed of 0.0012 without the presence 
of CA. Much faster hydrolysis was observed in solutions with CA-ZnO (0.0027 for CA-
ZnO produced in pH 7.5 and 0.0060 for CA-ZnO fabricated in pH 8.0). CA-ZnO 
immobilized in pH8.0 buffer showed the highest catalitic activitiy. CA-ZnO activity is in 
accordance with the CA immobilization ratio. The higher the CA immobilization ratio, 
the more active the obtained CA-ZnO would be. 
5.1.4 Immobilized CA for CO2 capture 
The amount of CO2 captured by CA-ZnO at different time points is shown in Figure 5.6.  
 
Figure 5.6 CO2 captured by CA-ZnO nanorods at different time points 
Using one 2.2×2.2 cm CA-ZnO as a catalyst, the catalyzed reaction reached equilibrium 
after 45 mins in 100 mL water, with the sequestration of 6 mmol CO2. The amount of 
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captured CO2 was analyzed by titration. The series of chemical reactions involved in the 
titration are shown as here: 
In the reactor, CO2 reacts with H2O and forms carbonic acid.  
                          
During the titration process, carbonic acid reacts gradually with sodium hydroxide and 
forms first sodium bicarbonate and then sodium carbonate. 
                         
                         
Phenolphthalein, which changes from colorless to pink when environmental pH is higher 
than 8.2, was applied to indicate the end point of the titration. At the end point, all H2CO3  
reacts with NaOH and forms alkaline Na2CO3, the Na2CO3 makes the color of 
phenolphthalein change from colorless to pink. 
 
Figure 5.7 Reusability of three 2.2×2.2 cm CA-ZnO in 100 mL water 
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To test the reusability of CA-ZnO, one CA-ZnO chip was used three times in 100 mL 
water to catalyze the CO2 capture. Figure 5.7 shows the reusability of three 2.2×2.2 cm 
CA-ZnO chips in 100 mL water.  
 In the first two times of test, despite the strong turbulence generated by pumping CO2 
into water, CA-ZnO maintained a similar ability to catalyze the H2CO3 genaration.  
During the third test, the H2CO3 genaration, which represented the CA catalytic ability, 
dropped nearly 50%.  
The possible reasons for the loss of CA activity are the erosion of the ZnO nanorod and 
the dissociation of CA from ZnO nanorods. They are possibily associated with the 
turbulence of reaction media. Further studies are needed to find a way to reduce the 
turbulence generated by pumping CO2 into the reaction media while keeping a constant 
CO2 input for the catalyzed reaction. 
5.2 Conclusions 
In this chapter, carbonic anhydrase (CA) was immobilized onto ZnO nanorods (ZnO) by 
a reversible denaturation process 
[9]
.  The immobilization was performed in a Tris-HCl 
buffer, and the immobilization ratio and the activity of immobilized CA were determined 
by the pH of the buffer. At pH 8.0, about 60% of CA in the buffer could be immobilized 
to the ZnO and the activity of CA is maintained. The CA immobilized ZnO nanorod (CA-
ZnO) was used to catalyze the reaction of CO2 with water. Using CO2 saturated water as 
reference, 6 mmol CO2 is captured in 100mL water by a 2.2×2.2 cm CA-ZnO chip with 
0.75 mg CA. This CA-ZnO chip could be used twice while keeping its activity in 
catalyzing the reaction of CO2 with water. At the third time of reuse, its active efficiency 
reduces nearly 50%. Further studies are needed to improve the reusability of the CA-ZnO 
chip. 
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Chapter 6 
Sustained Protein Delivery with Nanoparticle-Hydrogel 
Nanocomposites 
In the pharmaceutical industry, nanoparticles are gaining popularity and many of them 
have been put in the clinical trial and commercialization 
[1,2]
. As a drug delivery system, 
nanoparticles are able to modify fundamental properties of loaded drugs such as stability, 
half-life, and immunogenicity; and significantly improve their therapeutic effects 
[3]
.    
Proteins, especially those with short half lives, are usually incorporated into nanoparticles 
in order to be protected from degradation 
[4, 5]
.  Due to the abundant moiteties absent in 
proteins, the protein incorporation process is possibly caused by multiple protein-
nanoparticle interactions, especially electrostatic forces and hydrogen bonds.    
Although one of the main advantages of nanoparticles is their improved systematic 
absorption, in some special cases, such systematic absorption should be preferably 
avoided 
[6]
.  Skin wound healing is an example of such a case. Skin wound healing is a 
process in which the skin tissue repairs itself after injury. A sustained topical application 
of therapeutic agents such as epidermal growth factor 
[7]
 can significantly promote this 
process.  
Regular wound dressings such as hydrogel can be used to provide topical drug delivery to 
wound beds. However, such wound dressings only demonstrate a very limited capacity to 
retain the release of loaded drugs 
[7, 8]
.  Nanoparticle based drug delivery systems were 
developed to provide a sustained drug release. These systems utilized PCL-PEG 
copolymer 
[9]
, chitosan 
[10] 
or multiple polymers 
[11]
. However, due to the systematic 
absorption at wound bed, these nanoparticles are unable to provide a prolonged topical 
drug release without being immobilized into wound dressings.  
In the research introduced in this chapter, to achieve a sustained topical drug release as 
well as an effective wound bed protection, protein loaded nanoparticles were embedded 
into HEMA hydrogel to form a new wound dressing. Basic fibroblast growth factor 
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(bFGF), a proven protein to accelerate wound healing and tissue regeneration 
[12]
, was 
selected as the model protein for this new wound dressing. 
6.1 Results and Discussion 
6.1.1 Synthesis of bFGF loaded nanoparticles 
TEM micrographs of chitosan and silica nanoparticles are shown in Figure 6.1. All of the 
obtained nanoparticles are spherical in shape and their particle sizes are 50±35 nm and 
30±6 nm for chitosan and silica nanoparticles respectively.  
 
 
 
 
 
 
 
                                 (a)                                                                     (b) 
Figure 6.1 TEM micrographs of chitosan (a) and silica nanoparticles (b) 
The nanoparticles were made by different methods and thus show diverse particle sizes 
(chitosan > silica) and size distributions (chitosan > silica). Without using any organic 
solvent, the chitosan nanoparticles were made in the most environmentally friendly way. 
Chitosan is polycationic in acidic media (PKa 6.5) and can interact with negatively 
charged tripolyphosphate ions. The interaction of chitosan with sodium tripolyphosphate 
leads to the formation of crosslinked chitosan nanoparticles 
[13]
.   
Silica nanoparticles are synthesized by the sol-gel process, which is widely applied to 
produce silica and metallic nanoparticles at mild conditions 
[14-16]
. This sol-gel process 
involves hydrolysis and condensation of tetraethyl orthosilicate (TEOS) in the presence 
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of ammonium hydroxide (NH4OH) as the catalyst. The hydrolysis of TEOS molecules 
form silanol groups. The condensation between the silanol groups and ethoxy groups 
creates siloxane bridges (Si-O-Si) that form entire silica structure. 
6.1.2 Incorporation of nanoparticles into HEMA hydrogel 
Poly-(2-hydroxyethyl methacrylate) (HEMA) is a low toxicity 
[17]
, non-degradable 
material 
[18]
. HEMA is an ideal tissue engineering material due to its good mechanical 
strength and elasticity 
[19]
. However, HEMA lacks functional groups to which biological 
molecules can be easily attached. Therefore, reactive comonomers, typically containing 
carboxyl and amino groups, are incorporated in the material 
[18]
. In this research, 2-
Aminoethyl Methacrylate (AEMA) was crosslinked to HEMA via ethylene glycol 
dimethylacrylate (EGDMA) by UV light radiation. The resultant product imparted 
HEMA with amino groups 
[20]
. 2,2-Dimethoxy-2-Phenylacetophenone (DMPA) worked 
as the photoinitiator.   
All the monomers were first dissolved in DMSO. After all the monomers were mixed 
homogeneous, nanoparticles were suspended in the solution of monomers to form a 
suspension for photopolymerization. After the reaction, monomers were crosslinked 
together to form a porous three dimensional scaffold. Nanoparticles were embedded in 
the scaffold to reach a sustained local drug release without entering into circulation and 
being absorbed by the system.   
6.1.3 Stability of bFGF in release medium 
The ratio of tested bFGF concentration to its original concentration Ci/C0 (Ci: bFGF 
concentration in the sample which was taken at time i, C0: original bFGF concentration 
380 pg/mL) represents its stability. The average values of Ci/C0 at different times are 
shown in Figure 6.2. 
 
69 
 
 
Figure 6.2 Stability of bFGF in release medium 
The Ci/C0 values varies between 0.75 and 0.8, the Ci values do not show a tendency to 
decrease with the increase of incubation time. The results suggest that bFGF is kept 
stable in the release buffer within 350 hours. Since SigmaFast protease inhibitor - pH7.4 
phosphate buffer solution can protect bFGF from degrading, it is a suitable medium to 
test bFGF release from its carriers. 
6.1.4 Release of bFGF from nanoparticles and nanocomposites 
The release profiles of bFGF from chitosan, silica nanoparticles and nanoparticle-HEMA 
nanocomposites are shown in Figure 6.3 and 6.4 respectively. The release of bFGF is 
represented by the ratio of bFGF concentration at time i (Ci) to the its maximum 
concentration (Cmax) . 
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Figure 6.3 Release of bFGF from chitoan nanoparticles (CN) and chitosan 
nanoparticle-HEMA nanocomposite (CN-HEMA) 
Chitosan nanoparticles showed a 230 hours sustained bFGF release with a burst within 
the first 8 hours. bFGF can be  associated to chitosan nanoparticles in three different 
ways: at the nanoparticle’s surface, in the core as a reversible complex, or in the core as 
an irreversible complex 
[21]
. bFGF release can be withheld by chitosan nanoparticles 
because chitosan is generally insoluble in neutral solutions and most organic solvents 
[22]
. 
The burst release was possibly a result of the detachment of bFGF from the 
nanoparticles’ surface. The sustained release after the first 8 hours might result from the 
separation of bFGF from its reversible complex with chitosan and the disintegration of 
chitosan or bFGF- chitosan irreversible complex. bFGF release can be withheld by 
chitosan because it is generally insoluble in neutral solutions and most organic solvents 
[22]
.  
bFGF release from CN-HEMA nanocomposite was faster than that of the chitosan 
nanoparticles; in 50 hours, the release of bFGF reached maximum value. This 
phenomenon was contradictory to our hypothesis. The possible reason is that chitosan 
nanoparticles are formed by electrostatic interaction, which is not a strong interaction like 
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a covalent bond. During the synthesis of CN-HEMA nanocomposite, chitosan 
nanoparticles undergo sonication dispersion, organic solvents, and UV radiation. Those 
interactions, especially sonication, may pose a negative influence on the integrity of 
chitosan nanoparticles and impair their ability to withhold the release of bFGF. 
 
Figure 6.4 Release of bFGF from silica nanoparticles (SN) and silica nanoparticle-
HEMA nanocomposite (SN-HEMA) 
Silica nanoparticles could achieve a 180 hours’ prolonged bFGF release without an initial 
burst like chitoan nanoparticles. Such prolonged release may be attributed to two 
characteristics of silica nanoparticles: (1) The large pore volume of silica nanoparticles 
allows for loading significant amounts of proteins into the particles. (2) The chemically 
and mechanically stable inorganic oxide framework of silica nanoparticles shelters the 
protein from degradation and denaturation 
[23]
. The ability of silica nanoparticles to 
withhold an initial burst release is also substantiated by other research papers 
[23,24]
. Such 
a release pattern may results from the high affinity of the silica nanoparticles to proteins. 
Once incorporated into the SN-HEMA nanocomposite, bFGF release accelerated, despite 
the fact that nanoparticles were embedded in a porous hydrogel scaffold. Other than 
futher reduce the bFGF release speed, the SN-HEMA could only maintain a 150 hour 
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sustained bFGF release. The possible explanation of this phenomenon is that the 
sonication process, which aimed to suspend silica nanoparticles in the hydrogel 
monomers, makes part of bFGF detach from the silica nanoparticles, the detached bFGF 
releases very fast in the hydrogel and causes the initial burst of the nanocomposite. 
6.1.5 Release mechanism 
The rate-controlling mechanisms of drug release from hydrophilic matrices are polymer 
dissolution (erosion) and diffusion of drug molecules across the polymer lay 
[25]
. A semi-
empirical equation has been used widely to differentiate the contributions of both 
mechanisms 
[26,27]
.  
 
Where Mt is the amount of drug released at time t, M the amount of drug in dosage form, 
Qt the fraction of drug released at t, n the diffusional exponent, and k the kinetic constant. 
If diffusion dominates polymer erosion, the value of n would approach 0.5. On the other 
hand, for erosion controlled formulations, n would approach the value of 1. Under a 
mixed condition, the value of n falls in between 0.5 and 1 when both diffusion and 
erosion occurs simultaneously.  
The above formula can be transformed into the following formula. The value of n can be 
calculated by linear regression.  
 
The results of the calculation and the concluded release mechanism of samples in part 
6.1.4 are listed in Table 6.1.  
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Table 6.1 Release mechanism of bFGF from different nanomaterials 
Sample n value Release mechanism 
CN 0.2707 Diffusion controlled release 
CN-HEMA 0.2937 Diffusion controlled release 
SN 0.8571 Erosion controlled release 
SN-HEMA 0.8879 Erosion controlled release 
Silica nanoparticles are highly robust and its porous surface provides an inorganic 
platform to house large amounts of protein 
[28]
. The non-biodegradable nature of siclica 
nanoparticles precludes the possibility of erosion during release. The contradiction can be 
explained by the fact that the semi-empirical equation we applied to investigate the 
release mechanism is devised for polymers. In other conditions, using of this equation 
may lead to incorrect results.   
6.2 Conclusions 
In this chapter, a nanoparticle-HEMA nanocomposite was created to work as a wound 
dressing with a sustained topical protein delivery. The protein model, fibroblast growth 
factor (bFGF), was incorporated within chitosan and silica nanoparticles through 
electrostatic interaction and hydrogen bond. To achieve a localized drug delivery, the 
bFGF loaded chitosan and silica nanoparticle were incorporated within HEMA hydrogel 
via photopolymerization. bFGF release from the chitosan and silica nanoparticles could 
last 230 and 180 hours, respectively. The nanoparticle-HEMA nanocomposites did not 
furture reduce the release rate of  bFGF; the chitosan nanoparticle-HEMA and silica 
nanoparticle-HEMA showed sustained bFGF release for 50 hours and 150 hours, 
respectively. bFGF release from chitosan nanoparticle and corresponding nanocomposite 
followed a diffusion controlled manner. The nanoparticle-HEMA synthesis process, 
which exposes nanoparticles to sonication, organic solvents, stong turbulence, and UV 
radiation, may compromise the bFGF-nanopaticle binding. The compromised bFGF-
nanopaticle binding makes bFGF release much faster from nanoparticle-HEMA than 
from nanoparticles. However, due to the fact that nanoparticle-HEMA nanocomposites 
makes localized sustained bFGF delivery possible, it can be concluded that these 
nanocomposites are promising wound dressings.    
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Chapter 7 
Conclusions and Future Work 
7.1 Conclusions 
Protein-nanomaterial complexes have been investigated for their potential applicaton as 
protein assay label, immobilized enzyme catalyst and localized drug delivery systems, 
respectively.    
First, a new AuNP assisted protein assay method was developed. Bovine serum albumin 
(BSA) was bound to AuNP (BSA-AuNP) through the interaction between gold and amide 
functional groups. The surface plasma resonance (SPR) of AuNP was used to detect the 
release profile of BSA-AuNPs from gelatin microspheres. Within the range of 0.03125 - 
0.5 mmol/L, SPR of AuNP showed a linear relationship to the concentration of BSA-
AuNP. The release profiles of BSA-AuNP from gelatin microspheres were mornitored 
for 12 hours. It was found that a diffusion mechanism dominants the BSA-AuNP release. 
Via the electrostatic interaction, carbonic anhydrase (CA) was immobilized onto ZnO 
nanorods (CA-ZnO). The pH value of immobilization medium is between the isoelectric 
point (pI) of CA (6.7-7.9) and ZnO (9.5).  The CA immobilization ratio and the activity 
of immobilized CA are dependent on the pH value of the immobilization buffer. 
Compared with pH 6.9 and pH 7.5 media, the pH 8.0 medium could achieve the highest 
CA immobilization ratio (60%), and the most active CA-ZnO. CA-ZnO produced in pH 
8.0 immobilization medium was used to catalyze the CO2 capture by water. Using CO2 
saturated water as reference, 6 mmol CO2 could be captured in 100mL water by a 2.2×2.2 
cm CA-ZnO chip immobilized with 0.75 mg CA. The CA-ZnO chip could maintain its 
activity for two times usage. 
Through electrostatic interaction and hydrogen bond, fibroblast growth factor (bFGF) 
was incorporated within chitosan and silica nanoparticles. Those bFGF loaded 
nanoparticles were further immobilized within HEMA hydrogel via photopolymerization. 
Chitosan and silica nanoparticles showed a sustained release of bFGF release for upto 
230 and 180 hours, respectively. The nanoparticle-HEMA nanocomposites did not future 
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reduce the release rate of bFGF. The release profile of chitosan nanoparticle-HEMA and 
silica nanoparticle-HEMA reached plateau at 50 and 150 hours, respectively. Release 
profiles of bFGF from chitosan nanoparticle and chitosan nanoparticle-HEMA follow the 
diffusion controlled manner. Due to their ability of providing a localized sustained bFGF 
delivery, these nanocomposites can be made into promising wound dressings.    
7.2 Future Work 
To get a clearer picture of how protein-nanoparticle interaction influences the application 
of protein loaded nanomaterials, several aspects of this research need futher investigation. 
1) Pre-labeling fixed amount of BSA with AuNP via chemical binding makes BSA 
detectable by measuring the SPR of AuNP.  However, this method does not help the 
detection of unknown amount of protein with AuNP. Grafting AuNP surfaces with 
protein antibodies could change the protein-AuNP interaction as well as the SPR 
properties of AuNP. The interaction of protein with its antibodies might bridge the 
separate AuNP and change its SPR. The change in SPR could be utilized to quantify 
unknown amounts of protein with AuNP probes.  
2) The static electrically immobilized CA-ZnO shows a limited service life in the CO2 
capture system (showed in Figure 3.2). Two methods could be applied to extend the 
service life of CA-ZnO: (a) ZnO could be surface modified to provide stronger binding 
sites for CA. (b) The CO2 capture system (showed in Figure 3.2) could be improved to 
reduce the turbulence.  
3) The static electrical and hydrogen binding of of bFGF to chitosan and silica 
nanoparticles are compromised by the series of processes to incorporate nanoparticles 
into HEMA hydrogel. To improve the release properties of nanoparticle-HEMA 
nanocomposites, future work could be carried out in two areas: (a) Nanoparticles could 
be surface modified to realize a more endurable bFGF-nanoparticle binding. (b) The 
procedure to produce dry nanoparticles as well as incorporate them into HEMA gel could 
be optimized to exclude the sonication resuspension step and to make the process a 
milder one.  
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